Fluid level indicator determination

Information

  • Patent Grant
  • 9615767
  • Patent Number
    9,615,767
  • Date Filed
    Thursday, October 21, 2010
    13 years ago
  • Date Issued
    Tuesday, April 11, 2017
    7 years ago
Abstract
A method for use in analyzing impedance measurements on a subject is described. The method can include, in a processing system, determining at least one impedance value at each of a number of frequencies, each impedance value representing the impedance of a segment of the subject, determining a dispersion parameter value indicative of a dispersion of the impedance values and, determining an indicator based at least on part on the dispersion parameter value.
Description
RELATED APPLICATIONS

This application is a U.S. National Phase under 35 U.S.C. §371 of the International Patent Application No. PCT/AU2010/001399, filed Oct. 21, 2010, and published in English on May 5, 2011 as WO 2011/050393, which claims the benefit of Australian Patent Application No. 2009905220, filed Oct. 26, 2009, both of which are incorporated by reference in their entirety.


BACKGROUND OF THE INVENTION

The present invention relates to a method and apparatus for use in analysing impedance measurements performed on a subject, and in particular to a method and apparatus for determining an indicator using a dispersion parameter, to thereby allow the indicator to be used in diagnosing the presence, absence or degree of oedema.


DESCRIPTION OF THE PRIOR ART

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.


One existing technique for determining biological parameters relating to a subject, such as fluid levels, involves the use of bioelectrical impedance. This involves measuring the electrical impedance of a subject's body using a series of electrodes placed on the skin surface. Changes in electrical impedance at the body's surface are used to determine parameters, such as changes in fluid levels, associated with the cardiac cycle or oedema, or other conditions which affect body habitus.


Lymphoedema is a condition characterised by excess protein and oedema in the tissues as a result of reduced lymphatic transport capacity and/or reduced tissue proteolytic capacity in the presence of a normal lymphatic load. Acquired, or secondary lymphoedema, is caused by damaged or blocked lymphatic vessels. The commonest inciting events are surgery and/or radiotherapy. However, onset of lymphoedema is unpredictable and may develop within days of its cause or at any time during a period of many years after that cause.


WO00/79255 describes a method of detection of oedema by measuring bioelectrical impedance at two different anatomical regions in the same subject at a single low frequency alternating current. The two measurements are analysed to obtain an indication of the presence of tissue oedema by comparing with data obtained from a normal population.


WO2005/122888 describes a method of detecting tissue oedema in a subject. The method includes determining a measured impedance for first and second body segments. An index indicative of a ratio of the extra-cellular to intra-cellular fluid is then calculated for each body segment, with these being used to determine an index ratio, based on the index for the first and second body segments. The index ratio can in turn be used to determine the presence, absence or degree of tissue oedema, for example by comparing the index ratio to a reference or previously determined index ratios.


WO2008/138602 describes a method for use in analysing impedance measurements performed on a subject, the method including, in a processing system determining at least one impedance value, representing the impedance of at least a segment of the subject, determining an indicator indicative of a subject parameter using the at least one impedance value and a reference and displaying a representation of the indicator.


SUMMARY OF THE PRESENT INVENTION

It is an object of the present invention to substantially overcome, or at least ameliorate, one or more disadvantages of existing arrangements.


In a first broad form the present invention seeks to provide a method for use in analysing impedance measurements performed on a subject, the method including, in a processing system:

    • a) determining at least one impedance value at each of a number of frequencies, each impedance value representing the impedance of a segment of the subject;
    • b) determining a dispersion parameter value indicative of a dispersion of the impedance values; and,
    • c) determining an indicator based at least in part on the dispersion parameter value.


Typically the method includes, in the processing system:

    • a) determining first and second dispersion parameter values for first and second body segments respectively; and,
    • b) determining the indicator using the first and second dispersion parameter values.


Typically the first body segment is an affected body segment and the second body segment is an unaffected body segment.


Typically at least one of the body segments is a dominant limb and the other body segment is a non-dominant limb.


Typically the first body segment is a different body segment to the second body segment.


Typically the method includes, in the processing system:

    • a) determining a predicted dispersion parameter value for the first body segment using the second dispersion parameter value;
    • b) determining the indicator using the first and predicted dispersion parameter values.


Typically predicted dispersion parameter value is determined to take into account at least one of:

    • a) limb dominance; and,
    • b) differences in limb types.


Typically the method includes, in the processing system, determining a predicted dispersion parameter value using at least one reference value derived from a reference normal population.


Typically the reference normal population is selected based on at least one of:

    • a) limb dominance;
    • b) differences in limb types;
    • c) ethnicity;
    • d) age;
    • e) gender;
    • f) weight; and,
    • g) height.


Typically the at least one reference value is determined based on a linear regression of first and second dispersion parameter values measured for the reference normal population.


Typically the method includes, in the processing system, determining the predicted dispersion parameter value using an equation of the form:

DPp=aDP2+K

    • where:
      • DP2 is the second dispersion parameter value
      • DPp is the predicted dispersion parameter value
      • a is a multiplier reference value determined based on a relationship between first and second dispersion parameter values in a reference population
      • K is a constant reference value determined based on a relationship between first and second dispersion parameter values in a reference population


Typically, for a male subject, the predicted value for a leg segment based on second dispersion parameters for an arm segment is based on:

    • a) a value of a in the range 0.15 to 0.022; and,
    • b) a value of K in the range 0.62 to 0.72.


Typically, for a female subject, the predicted value for a leg segment based on second dispersion parameters for an arm segment is based on:

    • a) a value of a in the range 0.44 to 0.41; and,
    • b) a value of K in the range 0.43 to 0.46.


Typically the method includes, in the processing system, determining the indicator using the equation:






Ind




=


sf
×

(


DP
p

-

DP
1


)



3

SE








    • where:
      • Ind is the indicator
      • DP1 is a dispersion parameter value determined for the body segment
      • DPp is a predicted dispersion parameter value for the body segment
      • sf is a scaling factor
      • SE is a standard error determined based on dispersion parameter values in a reference population





Typically the method includes, in the processing system, determining the indicator using the equation:






Ind




=


sf
×

(


DP
μ

-

DP
1


)



3

SE








    • where:
      • DPμ is the mean dispersion parameter value for a reference normal population
      • DP1 is a dispersion parameter value determined for the body segment
      • sf is a scaling factor
      • SE is a standard error determined for the dispersion parameter values for the reference population





Typically the scaling factor is selected so that a threshold value indicative of the presence or absence of oedema is an integer value.


Typically the method includes, in the processing system, determining the indicator based on the equation:

Ind=sf(DP2−DP1)

    • where:
      • Ind is the indicator
      • DP1 is a first dispersion parameter value for a first body segment
      • DP2 is a second dispersion parameter value for a second body segment
      • sf is a scaling factor


Typically the dispersion parameter value is indicative of the distribution of impedance measurements for the respective body segment.


Typically the dispersion parameter is based on the value of at least one of:






DP
=


(


R
0

-

R



)


X
c








DP
=


X
c


(


R
0

-

R



)








DP
=


(


R


-

R
0


)


X
c








DP
=


X
c


(


R


-

R
0


)








    • where:
      • R=impedance at infinite applied frequency;
      • R0=impedance at zero applied frequency;
      • Xc=reactance at the centre of the circle.





Typically the dispersion parameter is based on the value of:






α
=


2
π


a





tan



(


R
0

-

R



)


2




X
c










Typically the indicator is at least one of:

    • a) an oedema indicator for use in assessing a presence, absence or degree of oedema in the subject.
    • b) a hydration indicator for use in assessing hydration levels in a subject.


Typically the method includes, in the processing system, displaying a representation of the indicator.


Typically representation of the indicator includes a linear scale including:

    • a) a linear indicator;
    • b) a scale; and,
    • c) a pointer, the pointer being positioned on the scale in accordance with the indicator.


Typically the method includes, in the processing system, displaying a representation including an indication of a change in indicator value from at least one of a previous indicator value and a baseline indicator value.


Typically the method includes, in the processing system:

    • a) determining at least one threshold using a reference; and,
    • b) displaying the threshold as part of the representation.


Typically the method includes, in the processing system:

    • a) determining two thresholds using a reference; and,
    • b) displaying the thresholds on the representation, the thresholds being indicative of a normal range.


Typically the method includes, in the processing system, displaying, on the representation, at least one of:

    • a) a normal range;
    • b) an intervention range;
    • c) a hydration range; and,
    • d) an oedema range.


Typically the method includes in the processing system, causing one or more impedance measurements to be performed.


Typically the method includes, in the processing system:

    • a) causing at least one excitation signal to be applied to the subject;
    • b) determining at least one signal measured across the subject; and,
    • c) determining at least one impedance value using an indication of the excitation signal and the signal measured across the subject.


Typically the method includes, in the processing system:

    • a) controlling a signal generator to thereby cause the at least one excitation signals to be applied to the subject; and,
    • b) determining the at least one signal measured across the subject using a sensor.


In a second broad form the present invention seeks to provide apparatus for use in analysing impedance measurements performed on a subject, the apparatus including a processing system for:

    • a) determining at least one impedance value at each of a number of frequencies, each impedance value representing the impedance of a segment of the subject;
    • b) determining a dispersion parameter value indicative of a dispersion of the impedance values; and,
    • c) determining an indicator based at least in part on the dispersion parameter value.


Typically the apparatus includes:

    • a) a signal generator for applying one or more electrical signals to the subject using a first set of electrodes;
    • b) a sensor for measuring electrical signals across a second set of electrodes applied to the subject; and,
    • c) a controller for:
      • i) controlling the signal generator; and,
      • ii) determining the indication of the measured electrical signals.


Typically the controller includes the processing system.


Typically the processing system includes the controller.


In a third broad form the present invention seeks to provide a method for use diagnosing the presence, absence or degree of oedema in a subject by using impedance measurements performed on the subject, the method including, in a processing system:

    • a) determining at least one impedance value at each of a number of frequencies, each impedance value representing the impedance of a segment of the subject;
    • b) determining a dispersion parameter value indicative of a dispersion of the impedance values;
    • c) determining an indicator based at least in part on the dispersion parameter value; and,
    • d) displaying a representation of the indicator, to thereby allow the presence, absence or degree of oedema in the subject to be assessed.


It will be appreciated that the broad forms of the invention may be used individually or in combination, and may be used for diagnosis of the presence, absence or degree of a range of conditions and illnesses, including, but not limited to oedema, lymphoedema, body composition and the like.





BRIEF DESCRIPTION OF THE DRAWINGS

An example of the present invention will now be described with reference to the accompanying drawings, in which:—



FIG. 1 is a schematic of an example of impedance determination apparatus;



FIG. 2 is a flowchart of an example of a process for determining an indicator;



FIG. 3A is a schematic of an example of a theoretical equivalent circuit for biological tissue;



FIG. 3B is an example of a locus of impedance known as a Wessel plot;



FIG. 4 is a flowchart of an example of a process for determining an oedema indicator for limb oedema;



FIGS. 5A and 5B are diagrams of examples of electrode positions for use in measuring limb impedances;



FIGS. 5C and 5D are schematic diagrams of examples of electrode positions for use in measuring limb impedances;



FIG. 6A to 6C are schematic diagrams of first examples of representations of oedema indicators;



FIG. 7 are graphs of examples of the relationship of parameters between like limbs and dislike limbs; and,



FIG. 8 is a graph of example measurements of leg α and arm α for healthy female dominant arms and legs.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

An example of apparatus suitable for performing an analysis of a subject's bioelectric impedance will now be described with reference to FIG. 1.


As shown the apparatus includes a measuring device 100 including a processing system 102, connected to one or more signal generators 117A, 117B, via respective first leads 123A, 123B, and to one or more sensors 118A, 118B, via respective second leads 125A, 125B. The connection may be via a switching device, such as a multiplexer, although this is not essential.


In use, the signal generators 117A, 117B are coupled to two first electrodes 113A, 113B, which therefore act as drive electrodes to allow signals to be applied to the subject S, whilst the one or more sensors 118A, 118B are coupled to the second electrodes 115A, 115B, which act as sense electrodes, allowing signals across the subject S to be sensed.


The signal generators 117A, 117B and the sensors 118A, 118B may be provided at any position between the processing system 102 and the electrodes 113A, 113B, 115A, 115B, and may be integrated into the measuring device 100. However, in one example, the signal generators 117A, 117B and the sensors 118A, 118B are integrated into an electrode system, or another unit provided near the subject S, with the leads 123A, 123B, 125A, 125B connecting the signal generators 117A, 117B and the sensors 118A, 118B to the processing system 102.


It will be appreciated that the above described system is a two channel device, used to perform a classical four-terminal impedance measurement, with each channel being designated by the suffixes A, B respectively. The use of a two channel device is for the purpose of example only, and multiple channel devices can alternatively be used to allow multiple body segments to be measured without requiring reattachment of electrodes. An example of such a device is described in copending patent application number WO2009059351.


An optional external interface 103 can be used to couple the measuring device 100, via wired, wireless or network connections, to one or more peripheral devices 104, such as an external database or computer system, barcode scanner, or the like. The processing system 102 will also typically include an I/O device 105, which may be of any suitable form such as a touch screen, a keypad and display, or the like.


In use, the processing system 102 is adapted to generate control signals, which cause the signal generators 117A, 117B to generate one or more alternating signals, such as voltage or current signals of an appropriate waveform, which can be applied to a subject S, via the first electrodes 113A, 113B. The sensors 118A, 118B then determine the voltage across or current through the subject S, using the second electrodes 115A, 115B and transfer appropriate signals to the processing system 102.


Accordingly, it will be appreciated that the processing system 102 may be any form of processing system which is suitable for generating appropriate control signals and at least partially interpreting the measured signals to thereby determine the subject's bioelectrical impedance, and optionally determine other information such as relative fluid levels, or the presence, absence or degree of conditions, such as oedema, lymphoedema, measures of body composition, cardiac function, or the like.


The processing system 102 may therefore be a suitably programmed computer system, such as a laptop, desktop, PDA, smart phone or the like. Alternatively the processing system 102 may be formed from specialised hardware, such as an FPGA (field programmable gate array), or a combination of a programmed computer system and specialised hardware, or the like, as will be described in more detail below.


In use, the first electrodes 113A, 113B are positioned on the subject to allow one or more signals to be injected into the subject S. The location of the first electrodes will depend on the segment of the subject S under study. Thus, for example, the first electrodes 113A, 113B can be placed on the thoracic and neck region of the subject S to allow the impedance of the chest cavity to be determined for use in cardiac function analysis. Alternatively, positioning electrodes on the wrist and ankles of a subject allows the impedance of limbs and/or the entire body to be determined, for use in oedema analysis, or the like.


Once the electrodes are positioned, one or more alternating signals are applied to the subject S, via the first leads 123A, 123B and the first electrodes 113A, 113B. The nature of the alternating signal will vary depending on the nature of the measuring device and the subsequent analysis being performed.


For example, the system can use Bioimpedance Spectroscopy (BIS) in which impedance measurements are performed at each of a number of frequencies ranging from very low frequencies (4 kHz) to higher frequencies (1000 kHz), and can use as many as 256 or more different frequencies within this range. Such measurements can be performed by applying a signal which is a superposition of plurality of frequencies simultaneously, or a number of alternating signals at different frequencies sequentially, depending on the preferred implementation. The frequency or frequency range of the applied signals may also depend on the analysis being performed.


In one example, the applied signal is generated by a voltage generator, which applies an alternating voltage to the subject S, although alternatively current signals may be applied. In one example, the voltage source is typically symmetrically arranged, with each of the signal generators 117A, 117B being independently controllable, to allow the signal voltage across the subject to be varied.


A voltage difference and/or current is measured between the second electrodes 115A, 115B. In one example, the voltage is measured differentially, meaning that each sensor 118A, 118B is used to measure the voltage at each second electrode 115A, 115B and therefore need only measure half of the voltage as compared to a single ended system.


The acquired signal and the measured signal will be a superposition of voltages generated by the human body, such as the ECG (electrocardiogram), voltages generated by the applied signal, and other signals caused by environmental electromagnetic interference. Accordingly, filtering or other suitable analysis may be employed to remove unwanted components.


The acquired signal is typically demodulated to obtain the impedance of the system at the applied frequencies. One suitable method for demodulation of superposed frequencies is to use a Fast Fourier Transform (FFT) algorithm to transform the time domain data to the frequency domain. This is typically used when the applied current signal is a superposition of applied frequencies. Another technique not requiring windowing of the measured signal is a sliding window FFT.


In the event that the applied current signals are formed from a sweep of different frequencies, then it is more typical to use a signal processing technique such as multiplying the measured signal with a reference sine wave and cosine wave derived from the signal generator, or with measured sine and cosine waves, and integrating over a whole number of cycles. This process, known variously as quadrature demodulation or synchronous detection, rejects all uncorrelated or asynchronous signals and significantly reduces random noise.


Other suitable digital and analogue demodulation techniques will be known to persons skilled in the field.


In the case of BIS, impedance or admittance measurements are determined from the signals to at each frequency by comparing the recorded voltage and the current through the subject. The demodulation algorithm can then produce amplitude and phase signals at each frequency, allowing an impedance value at each frequency to be determined.


As part of the above described process, the distance between the second electrodes 115A, 115B may be measured and recorded. Similarly, other parameters relating to the subject may be recorded, such as the height, weight, age, sex, health status, any interventions and the date and time on which they occurred. Other information, such as current medication, may also be recorded. This can then be used in performing further analysis of the impedance measurements, so as to allow determination of the presence, absence or degree of oedema, to assess body composition, or the like.


The accuracy of the measurement of impedance, can be subject to a number of external factors. These can include, for example, the effect of capacitive coupling between the subject and the surrounding environment, the leads and the subject, the electrodes, or the like, which will vary based on factors such as lead construction, lead configuration, subject position, or the like. Additionally, there are typically variations in, the impedance of the electrical connection between the electrode surface and the skin (known as the “electrode impedance”), which can depend on factors such as skin moisture levels, melatonin levels, or the like. A further source of error is the presence of inductive coupling between different electrical conductors within the leads, or between the leads themselves.


Such external factors can lead to inaccuracies in the measurement process and subsequent analysis and accordingly, it is desirable to be able to reduce the impact of external factors on the measurement process.


One form of inaccuracy that can arise is caused by the voltages across the subject being unsymmetrical, a situation referred to as an “imbalance”. Such a situation results in a significant signal voltage at the subject's body centre, which in turn results in stray currents arising from parasitic capacitances between the subject's torso and the support surface on which the subject is provided.


The presence of an imbalance, where the voltage across the subject is not symmetrical with respect to the effective centre of the subject, leads to a “common mode”, signal, which is effectively a measure of the signal at the subject. S that is unrelated to the subject's impedance.


To help reduce this effect, it is therefore desirable for signals to be applied to the subject S that they result in a symmetrical voltage about the subject's body centre. As a result, a reference voltage within the subject S, which is equal to a reference voltage of the measurement apparatus, will be close to the effective body centre of the subject, as considered relative to the electrode placement. As the measuring device reference voltage is typically ground, this results in the body centre of the subject S being as close to ground as possible, which minimises the overall signal magnitude across the subject's torso, thereby minimising stray currents.


In one example, a symmetrical voltage about the sensing electrodes cats be achieved by using a symmetrical voltage source, such as a differential bidirectional voltage drive scheme, which applies a symmetrical voltage to each of the drive electrodes 113A, 113B. However, this is not always effective if the contact impedances for the two drive electrodes 113A, 113B are unmatched, or if the impedance of the subject S varies along the length of the subject S, which is typical in a practical environment.


In one example, the apparatus overcomes this by adjusting the differential voltage drive signals applied to each of the drive electrodes 113A, 113B, to compensate for the different electrode impedances, and thereby restore the desired symmetry of the voltages across the subject S. This process is referred to herein as balancing and in one example, helps reduce the magnitude of the common mode signal, and hence reduce current losses caused by parasitic capacitances associated with the subject.


The degree of imbalance, and hence the amount of balancing required, can be determined by monitoring the signals at the sense electrodes 115A, 115B, and then using these signals to control the signal applied to the subject via the drive electrodes 113A, 113B. In particular, the degree of imbalance can be calculated by determining an additive voltage from the voltages detected at the sense electrodes 115A, 115B.


In one example process, the voltages sensed at each of the sense electrodes 115A, 115B are used to calculate a first voltage, which is achieved by combining or adding the measured voltages. Thus, the first voltage can be an additive voltage (commonly referred to as a common mode voltage or signal) which can be determined using a differential amplifier.


In this regard, a differential amplifier is typically used to combine two sensed voltage signals Va, Vb, to determine a second voltage, which in one example is a voltage differential Va−Vb across the points of interest on the subject S. The voltage differential is used in conjunction with a measurement of the current flow through the subject to derive impedance values. However, differential amplifiers typically also, provide a “common mode” signal (Va+Vb)/2, which is a measure of the common mode signal.


Whilst differential amplifiers include a common mode rejection capability, this is generally of only finite effect and typically reduces in effectiveness at higher frequencies, so a large common mode signal will produce an error signal superimposed on the differential signal.


The error caused by common mode signals can be minimised by calibration of each sensing channel. In the ideal case where both inputs of a differential amplifier are perfectly matched in gain and phase characteristics and behave linearly with signal amplitude, the common mode error will be zero. In one example, the two sensing channels of the differential amplifier are digitised before differential processing. It is therefore straightforward to apply calibration factors independently to each channel to allow the characteristics to be matched to a high degree of accuracy, thereby achieving a low common mode error.


Accordingly, by determining the common mode signal, the applied voltage signals can be adjusted, for example by adjusting the relative magnitude and/or phase of the applied signals, to thereby minimise the common mode signal and substantially eliminate any imbalance. An example of this process is described in more detail in copending patent application number WO2009059351.


An example of the operation of the apparatus in analysing impedance measurements will now be described with reference to FIG. 2.


In one example, at step 200 the processing system 102 causes a current signal to be applied to the subject S, with the induced voltage across the subject S being measured at step 210, with signals representing the measured voltage and the applied current being returned to the processing system 102 for analysis.


When the process is being used to determine an oedema indicator, this is typically performed for at least a segment of the subject S that is suspected of being susceptible to oedema, and may also be repeated for a separate healthy segment of the subject. Thus, for example, in the case of limb oedema, this is typically performed on the affected or “at risk” limb (hereinafter generally referred to as the “affected” limb), and a limb that is deemed “not at risk” of oedema (hereinafter generally referred to as the “unaffected” limb).


It will be appreciated that the application of the current and voltage signals may be controlled by a separate processing system that is used in performing the analysis to derive an indicator, and that the use of a single processing system is for the purpose of example only.


At step 220, measured voltage and current signals are used by the processing system 102 to determine impedance values at each of a number of applied frequencies. In one example, this includes first impedance values representing the impedance of the unaffected limb and second impedance values representing the impedance of the affected limb.


At step 230, the one or more impedance values are used by the processing system 102, to determine a dispersion parameter value. In one example, first and second dispersion parameter values of affected and unaffected limbs may be determined.


The nature of the dispersion parameter can vary, but in general this represents a distribution of the impedance measurements about an ideal model.


In one example, the dispersion parameter DP can be given by or based on the value:









DP
=


X
c


(


R
0

-

R



)






(
1
)









    • where:
      • R=impedance at infinite applied frequency;
      • R0=impedance at zero applied frequency;
      • Xc=reactance at the centre of the circle.





It should be noted that the value of Xc will be negative, due to it's position below the circle, and this can lead to the value of the dispersion parameter being negative. However, it will be appreciated that alternative formulations may also be used, such as those set out below, and accordingly, the dispersion parameter can be arranged to have either a positive or negative value, as desired:










D





P

=


(


R
0

-

R



)


X
c






(

1

A

)







D





P

=


(


R


-

R
0


)


X
c






(

1

B

)







D





P

=


X
c


(


R


-

R
0


)






(

1

C

)







The alternative formulations can be used to ensure that the value of the dispersion parameter increases in the event that the subject has oedema, although this is not essential and any suitable formulation may be selected.


In one particular example, the dispersion parameter DP value is given by a value α:









α
=


2
π


arctan



(


R
0

-

R



)


2




X
c










(
2
)







In this regard, FIG. 3A is an example of an equivalent circuit that effectively models the electrical behaviour of biological tissue. The equivalent circuit has two branches that represent current flow through extracellular fluid and intracellular fluid, respectively. The extracellular fluid component of biological impedance is represented by an extracellular resistance Re, whilst the intracellular fluid component is represented by an intracellular resistance Ri and a capacitance C representative of the cell membranes.


The relative magnitudes of the extracellular and intracellular components of impedance of an alternating current (AC) are frequency dependent. At zero frequency the capacitor acts as a perfect insulator and all current flows through the extracellular fluid, hence the resistance at zero frequency, R0, equals the extracellular resistance Re. At infinite frequency the capacitor acts as a perfect conductor and the current passes through the parallel resistive combination. The resistance at infinite frequency R is given by:










R


=



R
e



R
i




R
e

+

R
i







(
3
)







Accordingly, the impedance of the equivalent circuit of FIG. 3A at an angular frequency ω, where ω=2π*frequency, is given by:









Z
=


R


+



R
0

-

R




1
+

(

j





ω





τ

)








(
4
)









    • where:
      • R impedance at infinite applied frequency
      • R0=impedance at zero applied frequency=Re and,
      • τ is the time constant of the capacitive circuit.





However, the above represents an idealised situation which does not take into account the fact that the cell membrane is an imperfect capacitor. Taking this into account leads to a modified model in which:









Z
=


R


+



R
0

-

R




1
+


(

j





ω





τ

)

α








(
5
)









    • where:
      • α has a value between 0 and 1 and can be thought of as an indicator of the deviation of a real system from the ideal model.





An example of the typical multi-frequency impedance response is shown in FIG. 3B. As frequency increases, the reactance increases to a peak and then decreases while the resistance continually decreases. This results in a circular locus with the centre of the circle below the x axis, as shown.


The α parameter is related to the depression of the Cole plot below the zero reactance axis. The value of α is indicative of the deviation from the ideal Cole equation (4) and is closely related to the spectral width of the distribution of relaxation times. This dispersion may be due to molecular interactions, cellular interactions, anisotropy and cell size as described in Grimnes, S. and O. G. Martinsen (2000). Bioimpedance and Bioelectricity Basics, Academic Press.


As described above, the value of the impedance parameter R0 is closely related to extra-cellular fluid levels while the impedance parameter value R is closely related to the total body fluid levels. Accordingly, (R0−R) is closely related to the intra-cellular fluid levels.


The reactance Xc is the reactance X at the centre of the circle which is a direct measure of the depression of the circular locus below the axis. It is closely related to the reactance at the characteristic frequency by the subtraction from the radius of the locus. At the characteristic frequency, the ratio of the current flow through the intra and extra cellular fluids is determined as a function of the ratio of the intra to extra cellular resistance, so that it is independent of the capacitance of the cell membrane. Accordingly, the reactance at the characteristic frequency can be used more accurately as an indicator of extra-cellular fluid levels. Since the reactance at the centre of the circle is directly related to the characteristic reactance, this value is also related to the intra and extra cellular fluid.


Accordingly, the dispersion parameter is not only related to a ratio of extra-cellular to intra-cellular fluid levels, but also takes into account deviation from an idealised equivalent circuit reflecting the distribution of relaxation times within the subject and so encompasses changes in cell structure. In contrast, if a direct ratio of intra-cellular to extra-cellular fluid is used as an index I this is typically calculated as shown in equation (6) below and therefore does not account for such deviations to the same extent.









I
=



R
i


R
e


=


R




R
0

-

R









(
6
)







As lymphoedema is characterised by the accumulation of extra-cellular fluid, the dispersion parameter is different between a healthy and oedema affected population, with the difference being more readily quantifiable than if a direct ratio of intra-cellular to extra-cellular, given by equation (6) is used.


An example of the propagation of errors in the calculation of a dispersion parameter alpha and a ratio of intra-cellular to extra-cellular fluid will now be described. In order to determine the propagation of errors, it is necessary to take into account typical measurement errors in different frequency ranges for a typical measurement device, and these are shown in Table 1 below.












TABLE 1





Frequency Range
Body Impedance
Impedance Error
Phase Error







  3-100 kHz
200-1100 Ohms
+/−1%
+/−1%


100-1000 kHz
200-1100 Ohms
+/−2%
+/−2%









In this instance, the relative error in the index I from equation (6) is given by:








Δ





I


I
I


=



Δ






R




R



+



Δ






R
0


+

Δ






R






R
0

+

R









Similarly the relative error in the indicator Ind from equation (1) is given by:








Δ





Ind

Ind

=



Δ






X
C



X
C


+



Δ






R
0


+

Δ






R






R
0

-

R









Given the typical errors specifications for the measuring devices outlined in Table 1 above, and taking example leg impedance measurements, this leads to example impedance parameter values of:

R0=372Ω±1%
R=25Ω±2%
XC=−28Ω±1%


Accordingly, this leads to errors of:








Δ





I

I

=


2
+



0.01
·
372

+

0.02
·
253



372
+
253



=

2.01

%










Δ





Ind

Ind

=


1
+



0.01
·
372

+

0.02
·
253



372
-
253



=

1.07

%






This demonstrates that the alpha parameter can be determined more accurately and should therefore be more sensitive to fluid level changes within the subject, and hence the presence absence or degree of oedema.


At step 240, the dispersion parameter can be used to determine an indicator. In one example; the indicator provides information relating to the subject, such as an indication of fluid levels within the subject. In one example, the indicator is in the form of a numerical value that depends on a reference, and which can be used to determine the presence, absence or degree of a condition, such as oedema.


In one particular example, the reference is at least partially based on the dispersion parameter of an unaffected body segment. In particular, if the affected body segment does not in fact have oedema, then the dispersion parameter will be similar to the dispersion parameter for the unaffected body segment, thereby minimising a difference between first and second dispersion parameters. In contrast if the affected body segment has oedema the fluid levels will differ to the fluid levels in the unaffected body segment, meaning that the difference between the first and second dispersion parameters increases. As a result, the magnitude of the difference in first and second dispersion parameters between first and second body segments can be indicative of the presence, absence or degree of oedema. Accordingly, by comparing the difference between the dispersion parameters of affected and unaffected body segments to a threshold amount, then this can therefore be used to determine the presence, absence or degree of oedema.


In one example, the difference is scaled by a scaling factor so that the indicator and the threshold can be a memorable value, such as an integer value, or the like. This can be achieved by calculating an indicator as follows:

Ind=sf(DP2−DP1)  (7)

    • where:
      • Ind is the indicator
      • DP1 is the first dispersion parameter value of the affected body segment
      • DP2 is the second dispersion parameter value of the unaffected body segment
      • sf is a scaling factor


However, a population study of healthy subjects has found inherent differences in fluid levels between different body segments, such as limbs, even in unaffected individuals. This can include slight differences in dispersion parameters due to limb dominance in limbs as well as differences arising if the unaffected and affected limbs are of different limb types, such as arms and legs. For example, the dispersion parameter for a subject's leg will typically differ to that of the subject's arm, even in the absence of oedema in both limbs.


Accordingly, when calculating the reference it is typical to determine a predicted dispersion parameter value for the affected limb based on the second dispersion parameter value determined for the unaffected limb. This is usually achieved using at least one reference value derived from a reference normal population, allowing the natural variations between limbs due to gender, limb dominance and different limb types to be accommodated.


In one particular example, the predicted dispersion parameter value is calculated based on parameters derived by performing a linear regression of first and second dispersion parameter values measured for a reference population. The predicted dispersion parameter value can then be determined using an equation of the form:

DPp=aDP2+K  (8)

    • where:
      • DP2 is the second dispersion parameter value
      • DPp is the predicted dispersion parameter value
      • a is a multiplier reference value determined based on a relationship between first and second dispersion parameter values for a reference population
      • K is a constant reference value determined based on a relationship between first and second dispersion parameter values for the reference population


In one example, for a male subject, the predicted value for a leg segment based on second dispersion parameters for an arm segment is based on a value of a in the range 0.15 to 0.022, and a value of K in the range 0.62 to 0.72. For a female subject, the predicted value for a leg segment based on second dispersion parameters for an arm segment is based on a value of a in the range 0.44 to 0.41, and a value of K in the range 0.43 to 0.46.


When a predicted dispersion parameter value is used, the indicator can be determined using the equation:









Ind
=


sf
×

(


D






P
p


-

D






P
1



)



3

S





E






(
9
)









    • where:
      • Ind is the indicator
      • DP1 is a dispersion parameter value determined for the body segment
      • DPp is a predicted dispersion parameter value for the body segment
      • sf is a scaling factor
      • SE is a standard error determined based on dispersion parameter values in a reference population





It should be noted that in the event that measurements are made for an affected body segment only, then the predicted dispersion parameter value could alternatively be based on a mean value obtained from a reference population, leading to an indicator of the form:









Ind
=


sf
×

(


D






P
μ


-

D






P
1



)



3

S





E






(
10
)









    • where:
      • DPμ is the mean dispersion parameter value for a reference normal population
      • sf is a scaling factor
      • SE is a standard error determined based on dispersion parameter values for the reference population





Accordingly, it will be appreciated that the above described dispersion parameter can be used in diagnosing the presence, absence or degree of oedema. Furthermore, in contrast to prior art techniques, a dispersion parameter tends to provide more reliable results, as will be discussed in more detail below.


In the above examples, it will be appreciated that the order of the dispersion parameters could be reversed, so that for example in equation (9) the predicted value could be subtracted from the measured value and this will depend on the nature of the dispersion parameter used, so for example whether the dispersion parameter is based on equations (1), (1A), (1B), (1C), (2), or variations thereof. In general the order used will be selected so that the indicator Ind increases in magnitude as the level of oedema increases, however this is not essential and any suitable arrangement may be used.


An example of the process for performing impedance measurements to determine an indicator for limb oedema will now be described in more detail with reference to FIG. 4.


In this example, at step 400 subject details are determined and provided to the processing system 102. The subject details will typically include information such as limb dominance, details of any medical interventions, as well as information regarding the subject such as the subject's age, weight, height, sex, ethnicity or the like. The subject details can be used in selecting a suitable reference normal population, as well as for generating reports, as will be described in more detail below.


It will be appreciated that the subject details may be supplied to the processing system 102 via appropriate input means, such as the I/O device 105. Thus, each time a subject measurement is performed this information can be input into the measuring device 100.


However, more typically the information is input a single time and stored in an appropriate database, or the like, which may be connected as a peripheral device 104 via the external interface 103. The database can include subject data representing the subject details, together with information regarding previous oedema indicators, baseline measurements or impedance measurements recorded for the subject.


In this instance, when the operator is required to provide subject details, the operator can use the processing system 102 to select a search database option allowing the subject details to be retrieved. This is typically performed on the basis of a subject identifier, such as a unique number assigned to the individual upon admission to a medical institution, or may alternatively be performed on the basis of name or the like. Such a database is generally in the form of an HL7 compliant remote database, although any suitable database may be used.


In one example, the subject can be provided with a wristband or other device, which includes coded data indicative of the subject identifier. In this case, the measuring device 100 can be coupled to a peripheral device 104, such as a barcode or RFID (Radio Frequency Identification) reader allowing the subject identifier to be detected and provided to the processing system 102, which in turn allows the subject details to be retrieved from the database. The processing system 102 can then display an indication of the subject details retrieved from the database, allowing the operator to review these and confirm their accuracy before proceeding further.


At step 410 the affected limb, or “at risk” limb, is determined. This may be achieved in any one of a number of ways depending on the preferred implementation. Thus, for example, the affected limb can be indicated through the use of appropriate input means, such as the I/O device 105. Alternatively this information can be derived directly from the subject details, which, may include an indication of the affected limb, or details of any medical interventions performed, which are in turn indicative of the affected limb.


At step 420 an operator positions the electrodes on the subject S, and connects the leads 123, 124, 125, 126, to allow the impedance measurements to be performed. The general arrangement is to provide electrodes on the hand at the base of the knuckles and between the bony protuberances of the wrist, as shown in FIG. 5A, and on the feet at the base of the toes and at the front of the ankle, as shown in FIG. 5B. The configurations shown in FIGS. 5C and 5D allow the right arm 531 and the right leg 533 to be measured respectively, and it will be appreciated that equivalent arrangements can be used to measure the impedance of the left leg and left arm.


It will be appreciated that this configuration uses the theory of equal potentials, allowing the electrode positions to provide reproducible results for impedance measurements. For example when current is injected between electrodes 113A and 113B in FIG. 5C, the electrode 115B could be placed anywhere along the left arm 532, since the whole arm is at an equal potential.


This is advantageous as it greatly reduces the variations in measurements caused by poor placement of the electrodes by the operator. It also greatly reduces the number of electrodes required to perform segmental body measurements, as well as allowing the limited connections shown to be used to measure each limb separately.


However, it will be appreciated that any suitable electrode and lead arrangement may be used.


At step 430 the impedance of the affected and unaffected limbs are measured. This is achieved by applying one or more current signals to the subject and then measuring the corresponding voltages induced across the subject S. It will be appreciated that in practice the signal generators 117A, 117B, and the sensors 118A, 118B, return signals to the processing system 102 indicative of the applied current and the measured voltage, allowing impedances to be determined.


Following at step 440 a dispersion parameter DP for each of the limbs is determined using equations (1) or (2) above.


At step 450 a reference is selected. The reference is typically derived from equivalent measurements made on a normal population (subject's not suffering from oedema) that is relevant to the subject under study. Thus, the normal population is typically selected taking into account factors such as medical interventions performed, ethnicity, sex, height, weight, limb dominance, the affected limb, or the like.


Therefore if the test subject is female having bilateral lymphoedema of the dominant leg then the normalised data drawn from the normal population database will be calculated from the dominant leg impedance ratio measurements from female subjects that are present in the normal population database.


Accordingly, at this stage the processing system 102 typically accesses reference populations stored in the database, or the like. This may be performed automatically by the processing system 102 using the subject details. Thus for example, the database may include a look-up table that specifies the normal population that should be used given a particular set of subject details. Alternatively selection may be achieved in accordance with predetermined rules that can be derived using heuristic algorithms based on selections made by medically qualified operators during previous procedures. Alternatively, this may be achieved under control of the operator, depending on the preferred implementation.


It will be appreciated by persons skilled in the art that operators may have their own reference stored locally. However, in the event that suitable references are not available, the processing system 102 can be used to retrieve a reference from a central repository, for example via an appropriate server arrangement. In one example, this may be performed on a pay per use basis.


Alternatively, in the event that a suitable reference is not available predetermined standard reference values may be used, as described above. However it will be appreciated that different values can be used as appropriate and that these values are for illustration only.


At step 460 a predicted dispersion parameter value for the affected body segment is determined using the second dispersion value derived for the unaffected body segment and the reference values, as described above with respect to equation (8).


Following this an indicator can be determined using equation (9) at step 470. As described above, this is typically achieved by scaling the difference between the predicted and measured dispersion parameter values for the affected arm. This is performed so that the value of the indicator at a threshold indicative of the presence of oedema corresponds to a memorable value. In one example, the scaling factor is set so that an indicator value of greater than “10” is indicative of oedema, whilst a value of below “10” is used to indicate an absence of oedema.


Representations of the indicator can then optionally be displayed at step 480. Examples of such representations for oedema indicators will now be described with reference to FIGS. 6A and 6B.


In these examples, the representation is in the form of a linear indicator 600, having an associated scale 601 and a pointer 602. The position of the pointer 602 relative to the scale 601 is indicative of the subject parameter, which in this example is based on an impedance ratio representing a ratio of fluid levels determined for healthy and affected limbs of the subject.


In the example of FIG. 6A, the indicator representation also includes a mean indicator 610 representing the mean indicator for the normal population, which is set to a value of “0” on the scale 601. The upper and lower thresholds are set to be three standard deviations from the mean 610, and are set to be positioned at “−10” and “+10” on the scale 601 respectively.


In use the lower and upper thresholds 611, 612 define a normal range 620, an investigation range 621, and an oedema range 622. The ranges can be indicated through the use of background colours on the linear indicator, so that for example, the normal range 620 is shaded green, whilst the investigation range 621 is unshaded, and the oedema range 622 is shaded red. This allows an operator to rapidly evaluate the positioning of the pointer 602 within the ranges, allowing for fast and accurate diagnosis of oedema based on the indicated fluid level information.


Thus, in the example of FIG. 6A, the pointer 602 is positioned at the value of 16.6, placing the pointer 602 in the oedema range 622, indicating to the user that the fluid levels in the subject S are probably indicative of oedema in the affected limb.


In this example, the linear indicator extends up to a value of “20” as this is able to accommodate the determined value of 16.6. However, it will be appreciated that the linear indicator can be extended to any value required to accommodate the determined indicator value. To ensure that the linear scale remains clear, particularly if an extreme indicator value is to be displayed, the linear indicator 600 may include discontinuities, allowing the scale to be extended to higher values. An example of this is shown in FIG. 6C, in which a discontinuity 605 is used to separate the linear indicator 600 into two portions 600A, 600B. In this example, the linear indicator portion 600A extends from “−10” to “+20”, whilst the second linear indicator portion 600B extends from “+70” to “+90”, thereby allowing an indicator value of “80” is to be displayed by appropriate positioning of the pointer 602 in the indicator portion 605B.


Whilst a linear indicator 600 is preferred as this easily demonstrates to the operator the potential degree of severity of any oedema, this is not essential, and alternatively the scale may be modified, particularly if an outlier indicator value is determined. Thus, for example, the linear indicator could include logarithmic scaling, or the like, over all or part of its length, to allow the determined indicator value to be displayed.


In the event that the indicator value is between “−10” and “+10”, this indicates that the subject S is within the normal range 620 and that therefore they do not have oedema. Finally, in the event that the indicator value is below “−10”, then the subject S is within the investigation range 621, indicating that the measurements need to be investigated further. In particular, it is extremely unlikely that, the affected limb could have an impedance value significantly smaller than that of the unaffected limb, and accordingly, this indicates that in all likelihood there has been an error in the measurement, such as incorrect designation of the affected limb, or incorrect connection of electrodes.


In the example of FIG. 6B, no reference is available, and accordingly, the representation does not includes a mean 610 or lower or upper thresholds 611, 612. In this instance, the indicator value is still scaled using default standard values. This may be used if the indicator is determined based on equation (7).


As a result an oedema indicator value of above “10” is still indicative of oedema, but may be a less reliable indicator than if the reference is available. To take this into account, the thresholds 611, 612, and hence the specific ranges 620, 621, 622, are excluded from the representation, highlighting to the operator that the scaled subject parameter value is indicative but not definitive of the subject's oedema status.


Experimental Examples

A survey of the normal population was conducted using an Impedimed SFB7 device to determine the “normal” values for the Cole parameters. 65 self diagnosed healthy females and 29, self diagnosed healthy males participated in a trial with the population demographics being shown in Table 2. The average and standard deviation of the Cole parameters for each limb was determined for both the dominant and non dominant limbs.












TABLE 2







Male
Female




















Age (years) μ(σ)
40.1 (13.2)
42.6 (11.7)



Height (cm) μ(σ)
179.6 (7.5) 
162.6 (21.3) 



Weight (kg) μ(σ)
86.6 (16.9)
69.4 (16.9)










Of the single Cole parameters, a is the parameter that has the lowest variation for all limbs within a normal population (COV=1-3%), thereby indicating that this is generally a more consistent parameter for healthy individuals.


The variation of some combinations of the Cole parameters was also investigated. The parameters with the lowest coefficient of variation in a control population were R0/R, R0/Xc. Ri/Re has a large coefficient of variation (10-15%) which suggests that this would make it difficult to use this impedance ratio to successfully distinguish between inherent variations within a subject, and variations induced by the presence of oedema or lymphoedema.


The normal arm to leg ratio calculated from the reference data for the same Cole parameters again results in the parameters having the lowest variation (<5%) being α, R0/R and R0/Xc.


To evaluate a bilateral approach, leg data from leg lymphoedema sufferers was obtained. Data was collected during a clinical trial in which 30 volunteers were invited to participate. Each subject was classified into the Control, Bilateral Lymphoedema or Unilateral Lymphoedema group based on provided medical history. Subjects were required to lie in a supine position while electrodes were attached to the hands and feet using standard placement markers. Three swept frequency bioimpedance measurements of each limb were recorded.


The population demographics are shown in Table 3 for the subjects who met eligibility criteria. The mean subject age was significantly higher than for the normal data previously collected in a healthy population. The mean heights for both trials are comparable and the mean weight for the control subjects was comparable to the normal data collected previously. However the unilateral and bilateral subjects recorded higher weights. This is to be expected as the amount of fluid in a leg affected by lymphoedema will contribute to the weight.













TABLE 3







Control (M/F)
Unilateral (M/F)
Bilateral (M/F)



















Gender
4/6
3/8
4/4


Age (years) μ(σ)
 59.3 (4.0)/48.5 (21.6)
61.4 (12.5)/59.1 (13.1)
63.0 (14.6)/65.8 (11.8)


Height (cm) μ(σ)
179.8 (2.4)/165.5 (6.7)
180.7 (4.0)/161.9 (10) 
177.5 (6.9)/163.5 (5.3)


Weight (kg) μ(σ)
 84.8 (3.8)/65.8 (11.1)
89.3 (10.2)/75.4 (15.2)
123.0 (31.1)/93.5 (24.8) 









A review of the COV in Table 2 suggests that other parameters other than Ri/Re are more stable within a normal population. These are the R0/R, Ro/Xc and α parameters.


An indicator was derived for each single limb from the R0/R, Ro/Xc and α parameters. The results for an indicator calculated based on α are shown in table 46, using a reference from a standard population. The indicator is calculated for each limb independently using a reference value for a obtain from the reference normal population, as shown in equation (10).















TABLE 4








Ind
Ind Non
Ind
Ind Non





Dom
Dom
Dom
Dom


Subject No
Gender
Group
Arm
Arm
Leg
Leg





















UB500-01-01
Female
Control
0.8
−0.1
−2.0
−1.3


UB500-01-09
Female
Control
−2.3
−3.0
−6.2
−5.4


UB500-01-13
Female
Control
−3.5
−0.6
−6.4
−6.5


UB500-01-14
Female
Control
−7.8
−5.8
−7.5
−9.1


UB500-01-24
Female
Control
−5.7
−2.3
−9.6
−7.4


UB500-01-25
Female
Control
2.3
3.3
−5.5
−1.7


UB500-01-02
Male
Control
−1.2
−0.1
−3.8
−4.2


UB500-01-17
Male
Control
−6.7
−11.5
−8.7
−11.0


UB500-01-23
Male
Control
−6.0
−2.8
−9.0
−5.2


UB500-01-29
Male
Control
1.7
6.5
−7.3
−2.6


UB500-01-04
Female
Uni
−3.4
−1.0
−7.6
−15.2


UB500-01-05
Female
Uni
−2.7
−6.3
−7.6
−15.0


UB500-01-12
Female
Uni
−3.9
−3.4
−14.4
−7.4


UB500-01-15
Female
Uni
0.4
0.1
−10.4
−29.8


UB500-01-22
Female
Uni
−9.0
−4.9
−16.8
−13.8


UB500-01-26
Female
Uni
−0.4
−1.4
−16.3
−11.9


UB500-01-28
Female
Uni
−2.1
1.7
−10.0
−4.9


UB500-01-08
Male
Uni
0.3
4.9
−15.0
−0.4


UB500-01-18
Male
Uni
−0.2
1.3
−16.9
−10.2


UB500-01-03
Female
Bi
−3.3
−1.2
−8.6
−8.6


UB500-01-07
Female
Bi
−3.2
−1.8
−23.6
−27.3


UB500-01-11
Female
Bi
−11.1
−12.3
−19.7
−21.2


UB500-01-19
Female
Bi
−5.2
−6.5
−34.9
−26.3


UB500-01-06
Male
Bi
0.6
5.5
−27.6
−32.2


UB500-01-10
Male
Bi
−20.0
−28.4
−27.5
−24.1


UB500-01-20
Male
Bi
−7.4
−22.7
−26.2
−19.9


UB500-01-27
Male
Bi
−1.7
2.6
−22.8
−20.0









In this example, the indicator values are negative as the reference dispersion parameter was subtracted from the measured value (the reverse situation to that shown in equation (10)) and as a decreases with an increase in lymphoedema. In this example, the scaling factor is selected so that −10 is an indication of lymphoedema.


Table 5 shows the specificity and sensitivity of the dispersion parameter α in being indicative of the presence of lymphodema. These results are greatly improved compared to using an Ri/Re, ratio for each limb. It should be noted that the sensitivity of the arms cannot be calculated as no affected arms were measured.














TABLE 5







Dom Arm
Non Dom Arm
Dom Leg
Non Dom Leg




















Specificity (%)
93
85
80
86


Sensitivity (%)
n/a
n/a
92
92









The biggest concern for this approach is the high indicator value recorded for three of the arms of the subjects. It would be expected that the indicator calculated for these unaffected arms would be within the normal range. In addition, the positive assessment of lymphoedema in some of the unaffected legs of the unilateral subjects may not be a false positive, but rather a sign that the lymphoedema is present in both legs.


The results highlight the ability to assess the presence of lymphoedema from the measurement of a single affected limb, meaning that this allows a technique to be implemented that requires only a single measurement of the affected limb.


Arm to leg ratios that resulted in a low coefficient of variation were again R0R, R0/Xc and α. From these, an indicator was calculated for the dominant and non dominant leg from the arm to leg ratios, similar to equation (7). The parameter that showed the greatest effectiveness is the ratio of arm to leg for the dispersion parameter α. Table 6 shows the specificity and sensitivity using this method is still low.












TABLE 6







Dom Leg
Non Dom Leg




















Specificity (%)
87
93



Sensitivity (%)
42
54










The above results suggest that perhaps the relationship between the arm and leg is not a one to one relationship. The ratio of affected to unaffected limb approach works well with unilateral lymphoedema as the affected limb is compared to an equivalent but contra-lateral limb. The ratio of unaffected limb to affected limb is very close to 1. This is the equivalent of assuming a linear relationship between the limbs without a constant offset. That is y=mx+c without the intercept c and where m is the normal ratio.


In essence this uses the healthy limb to predict what we would expect the affected limb to be if it were also unaffected. The deviation of the expected result from the measured result is then compared to the normal variation within a healthy population to assess the presence of lymphoedema. In the case of comparing an arm to a leg, there are a number or differences in geometry and structure such as cross sectional area and length. This would indicate an additional offset between the two measurements and suggest that the relationship between arms and legs may be linear. These concepts are shown graphically in FIG. 7.


An example of the variation of a normal leg α with normal arm α is shown for dominant arms and legs for healthy females in FIG. 8. This data is collected using the ImpediMed SFB7. No outliers have been rejected in this instance.


Regression analysis was performed on the healthy male and female, dominant and non dominant limb data to determine the line of best fit for the chosen parameters. The female normal data shows a stronger association (R>0.5) than the male data (R=0.2) for all parameters.


The resulting linear equations used to predict leg data from arm data are grouped by gender and dominance. The best performing parameter is α. The equations are shown below.

Female Dominant: αleg=0.4416αarm+0.4379,SE=0.0136
Female Non Dominant: αleg=0.4176αarm+0.4581,SE=0.0136
Male Dominant: αleg=0.1572αarm+0.6227,SE=0.0113
Male Non Dominant: αleg=0.0217αarm+0.7145,SE=0.0109


These regression equations were then used to predict the expected leg α from the measured arm α, using equation (8) above. Next the predicted leg α was subtracted from the measured leg α. This difference between the actual and predicted result was then compared to the standard error for a normal population. An indicator value was calculated according to equation (9).


Example results for leg α predicted from arm measurements are shown in Table 7.













TABLE 7









Indicator





indicator
Non Dom


Subject No
Gender
Group
Dom Leg
Leg



















UB500-01-01
Female
Control
2.8
1.5


UB500-01-09
Female
Control
7.4
6.4


UB500-01-13
Female
Control
5.2
7.3


UB500-01-14
Female
Control
3.9
6.8


UB500-01-24
Female
Control
7.6
7.3


UB500-01-25
Female
Control
2.4
5.4


UB500-01-02
Male
Control
6.5
3.9


UB500-01-17
Male
Control
6.8
7.5


UB500-01-23
Male
Control
6.9
6.0


UB500-01-29
Male
Control
9.4
3.0


UB500-01-04
Female
Uni
6.7
17.4


UB500-01-05
Female
Uni
7.2
13.5


UB500-01-12
Female
Uni
19.7
8.5


UB500-01-15
Female
Uni
12.3
35.3


UB500-01-22
Female
Uni
14.1
13.0


UB500-01-26
Female
Uni
16.7
21.2


UB500-01-28
Female
Uni
16.0
28.5


UB500-01-08
Male
Uni
10.3
7.1


UB500-01-18
Male
Uni
14.5
4.5


UB500-01-03
Female
Bi
8.0
9.5


UB500-01-07
Female
Bi
32.8
37.6


UB500-01-11
Female
Bi
16.2
16.8


UB500-01-19
Female
Bi
48.7
36.0


UB500-01-06
Male
Bi
24.9
30.5


UB500-01-10
Male
Bi
15.4
13.5


UB500-01-20
Male
Bi
27.5
20.3


UB500-01-27
Male
Bi
24.4
20.6









These results highlight that the use of the dispersion parameter α together with the prediction of an expected value for the affected limb based on measurements for the unaffected limb provide a high reliability of identification of lymphoedema as highlighted by sensitivity and specificity measures shown in Table 8. Of all methods presented, the results demonstrate the highest specificity and sensitivity.












TABLE 8







Dom Leg
Non Dom Leg




















Specificity (%)
80
93



Sensitivity (%)
92
92










It should be noted that Bilateral subject UB500-01-03 did not record an indicator of greater than 10. This can be explained as the subject had a very mild case of lymphoedema affecting only the upper most part of the thigh. It is expected that the contribution of the lymphoedema to the measured bioimpedance was not significant to be greatly altered from the normal state. However it will be noticed that in both legs an indicator score was, obtained that was greater than 8.


The remaining unilateral subjects whose unaffected leg produced an indicator of greater than 10, are potentially showing signs of developing lymphoedema in the other leg.


Accordingly, this highlights that using a dispersion parameter has been shown to produce the best results in predicting the presence of lymphoedema.


Persons skilled in the art will appreciate that numerous variations and modifications will become apparent. All such variations and modifications which become apparent to persons skilled in the art, should be considered to fall within the spirit and scope that the invention broadly appearing before described.


Thus, for example, it will be appreciated that features from different examples above may be used interchangeably where appropriate. Furthermore, whilst the above examples have focussed on a subject such as a human, it will be appreciated that the measuring device and techniques described above can be used with any animal, including but not limited to, primates, livestock, performance animals, such race horses, or the like.


The above described processes can be used for determining the health status of an individual, including the body composition of the individual, or diagnosing the presence, absence or degree of a range of conditions and illnesses, including, but not limited to oedema, lymphoedema, or the like. It will be appreciated from this that whilst the above examples use the term oedema indicator, this is for the purpose of example only and is not intended to be limiting. Accordingly, the oedema indicator can be referred to more generally as an indicator when used in analysing impedance measurements with respect to more general health status information such as body composition, or the like.

Claims
  • 1. A method for use in diagnosing a presence, absence or degree of oedema in a subject suspected of having the oedema by using impedance measurements performed on the subject, the method being performed using an apparatus including: a first set of electrodes for applying to the subject;a signal generator for applying excitation electrical signals to the subject using the first set of electrodes;a second set of electrodes for applying to the subject;a sensor for measuring measured electrical signals across the second set of electrodes; and,a processing system including at least one of a programmable computer system or a field-programmable gate array,the method including, in the processing system:causing the impedance measurements to be performed by: causing the excitation electrical signals to be applied to the subject using the signal generator;determining the measured electrical signals across the subject using the sensor; and,determining, using an indication of the excitation electrical signals and an indication of the measured electrical signals, impedance values at each of a number of frequencies for first and second body segments of the subject, each impedance value representing an impedance of the respective body segment, wherein the first body segment is a body segment of the subject that is suspected of being affected by the oedema and the second body segment is a body segment of the subject that is suspected of being unaffected by the oedema;determining impedance parameter values for the first and second body segments based on the impedance values for the respective body segment, the impedance parameter values including: R∞ representing an impedance at infinite applied frequency;R0 representing an impedance at zero applied frequency; and,Xc representing a reactance at a centre of a circle defined by the impedance values for the respective body segment;determining first and second dispersion parameter values for the first and second body segments respectively, each dispersion parameter value being indicative of a dispersion of the impedance values for the respective body segment, each dispersion parameter value being based on a ratio of: a difference between R∞ and R0 for the respective body, and,Xc for the respective body segment;determining an indicator using the first and the second dispersion parameter values; and,displaying a representation of the indicator, to thereby allow the presence, the absence or the degree of the oedema in the subject to be diagnosed.
  • 2. A method according to claim 1, wherein at least one of the first and second body segments is a dominant limb and the other of the first and second body segments is a non-dominant limb.
  • 3. A method according to claim 1, wherein the method includes, in the processing system: determining a predicted dispersion parameter value for the first body segment using the second dispersion parameter value; and,determining the indicator using the first and predicted dispersion parameter values.
  • 4. A method according to claim 3, wherein the predicted dispersion parameter value is determined to take into account at least one of: limb dominance; and,differences in limb types.
  • 5. A method according to claim 3, wherein the method includes, in the processing system, determining the predicted dispersion parameter value using at least one reference value derived from a reference normal population.
  • 6. A method according to claim 5, wherein the reference normal population is selected based on at least one of: limb dominance;differences in limb types;ethnicity;age;gender;weight; and,height.
  • 7. A method according to claim 5, wherein the at least one reference value is determined based on a linear regression of the first and second dispersion parameter values measured for the reference normal population.
  • 8. A method according to claim 3, wherein the method includes, in the processing system, determining the predicted dispersion parameter value using an equation of the form: DPp=aDP2+K, where: DP2 is the second dispersion parameter value;DPp is the predicted dispersion parameter value;a is a multiplier reference value determined based on a relationship between the first and second dispersion parameter values in a reference population; and,K is a constant reference value determined based on the relationship between the first and second dispersion parameter values in the reference population.
  • 9. A method according to claim 8, wherein the first body segment is a leg segment of the subject and the second body segment is an arm segment of the subject, and, for a male subject, the predicted dispersion parameter value for the leg segment based on the second dispersion parameter value for the arm segment is based on: a value of a in a range 0.15 to 0.022; and,a value of K in a range 0.62 to 0.72.
  • 10. A method according to claim 8, wherein the first body segment is a leg segment of the subject and the second body segment is an arm segment of the subject, and, for a female subject, the predicted dispersion parameter value for the leg segment based on the second dispersion parameter value for the arm segment is based on: a value of a in a range 0.44 to 0.41; and,a value of K in a range 0.43 to 0.46.
  • 11. A method according to claim 3, wherein the method includes, in the processing system, determining the indicator using the equation:
  • 12. A method according to claim 11, wherein the scaling factor is selected so that a threshold value indicative of the presence or the absence of the oedema is an integer value.
  • 13. A method according to claim 3, wherein the method includes, in the processing system, determining the indicator using the equation:
  • 14. A method according to claim 1, wherein the method includes, in the processing system, determining the indicator based on the equation: Ind=sf(DP2−DP1)where: Ind is the indicator;DP1 is the first dispersion parameter value for the first body segment;DP2 is the second dispersion parameter value for the second body segment; and,sf is a scaling factor.
  • 15. A method according to claim 1, wherein each dispersion parameter value is indicative of a distribution of the impedance measurements for the respective body segment.
  • 16. A method according to claim 1, wherein the dispersion parameter is based on the value of:
  • 17. A method according to claim 1, wherein the representation of the indicator includes a linear scale including: a linear indicator;a scale; and,a pointer, the pointer being positioned on the scale in accordance with the indicator.
  • 18. A method according to claim 17, wherein the method includes, in the processing system, displaying the representation including an indication of a change in indicator value from at least one of a previous indicator value and a baseline indicator value.
  • 19. A method according to claim 1, wherein the method includes, in the processing system: determining at least one threshold using a reference; and,displaying the at least one threshold as part of the representation.
  • 20. Apparatus for use in diagnosing a presence, absence or degree of oedema in a subject suspected of having the oedema by using impedance measurements performed on the subject, the apparatus including: a first set of electrodes for applying to the subject;a signal generator for applying excitation electrical signals to the subject using the first set of electrodes;a second set of electrodes for applying to the subject;a sensor for measuring measured electrical signals across the second set of electrodes; and,a processing system including a processor, a memory, and an I/O device, the processing system for: causing the impedance measurements to be performed by: causing the excitation electrical signals to be applied to the subject using the signal generator;determining the measured electrical signals across the subject using the sensor; and,determining, using an indication of the excitation electrical signals and an indication of the measured electrical signals, impedance values at each of a number of frequencies for first and second body segments of the subject, each impedance value representing an impedance of the respective body segment, wherein the first body segment is a body segment of the subject that is suspected of being affected by the oedema and the second body segment is a body segment of the subject that is suspected of being unaffected by the oedema;determining impedance parameter values for the first and second body segments based on the impedance values for the respective body segment, the impedance parameter values including: R∞ representing an impedance at infinite applied frequency;R0 representing an impedance at zero applied frequency; and,Xc representing a reactance at a centre of a circle defined by the impedance values for the respective body segment;determining first and second dispersion parameter values for the first and second body segments respectively, each dispersion parameter value being indicative of a dispersion of the impedance values for the respective body segment, each dispersion parameter value being based on a ratio of: a difference between R∞ and R0 for the respective body segment, and,Xc for the respective body segment;determining an indicator using the first and the second dispersion parameter values; and,displaying a representation of the indicator, to thereby allow the presence, the absence or the degree of the oedema in the subject to be diagnosed.
  • 21. A method for use in diagnosing a presence, absence or degree of oedema in a subject suspected of having the oedema by using impedance measurements performed on the subject, the method being performed using an apparatus including: a first set of electrodes for applying to the subject;a signal generator for applying excitation electrical signals to the subject using the first set of electrodes;a second set of electrodes for applying to the subject;a sensor for measuring measured electrical signals across the second set of electrodes; and,a processing system including a processor, a memory, and an I/O device, the method including, in the processing system:causing the impedance measurements to be performed by: causing the excitation electrical signals to be applied to the subject using the signal generator;determining the measured electrical signals across the subject using the sensor; and,determining, using an indication of the excitation electrical signals and an indication of the measured electrical signals, impedance values at each of a number of frequencies for first and second body segments of the subject, each impedance value representing an impedance of the respective body segment, wherein the first body segment is a body segment of the subject that is suspected of being affected by the oedema and the second body segment is a body segment of the subject that is suspected of being unaffected by the oedema;determining impedance parameter values for the first and second body segments based on the impedance values for the respective body segment, the impedance parameter values including: R∞ representing an impedance at infinite applied frequency;R0 representing an impedance at zero applied frequency; and,Xc representing a reactance at a centre of a circle defined by the impedance values for the respective body segment;determining first and second dispersion parameter values for the first and second body segments respectively, each dispersion parameter value being indicative of a dispersion of the impedance values for the respective body segment, each dispersion parameter value being based on a ratio of: a difference between R∞ and R0 for the respective body segment, and,Xc for the respective body segment;determining an indicator using the first and the second dispersion parameter values; and,displaying a representation of the indicator, to thereby allow the presence, the absence or the degree of the oedema in the subject to be diagnosed.
Priority Claims (1)
Number Date Country Kind
2009905220 Oct 2009 AU national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/AU2010/001399 10/21/2010 WO 00 8/3/2012
Publishing Document Publishing Date Country Kind
WO2011/050393 5/5/2011 WO A
US Referenced Citations (468)
Number Name Date Kind
3316896 Thomasset May 1967 A
3851641 Toole et al. Dec 1974 A
3866600 Rey Feb 1975 A
3868165 Gonser Feb 1975 A
3871359 Pacela Mar 1975 A
4008712 Nyboer Feb 1977 A
4034854 Bevilacqua Jul 1977 A
4082087 Howson Apr 1978 A
4121575 Mills et al. Oct 1978 A
4144878 Wheeler Mar 1979 A
RE30101 Kubicek et al. Sep 1979 E
4169463 Piquard Oct 1979 A
4184486 Papa Jan 1980 A
4233987 Feingold Nov 1980 A
4291708 Frei et al. Sep 1981 A
4314563 Wheeler Feb 1982 A
4353372 Ayer Oct 1982 A
4365634 Bare et al. Dec 1982 A
4407288 Langer et al. Oct 1983 A
4407300 Davis Oct 1983 A
4450527 Sramek May 1984 A
4458694 Sollish et al. Jul 1984 A
4486835 Bai et al. Dec 1984 A
4537203 Machida Aug 1985 A
4539640 Fry et al. Sep 1985 A
4557271 Stoller et al. Dec 1985 A
4583549 Manoli Apr 1986 A
4602338 Cook Jul 1986 A
4617939 Brown et al. Oct 1986 A
4638807 Ryder Jan 1987 A
4646754 Seale Mar 1987 A
4686477 Givens et al. Aug 1987 A
4688580 Ko et al. Aug 1987 A
4763660 Kroll et al. Aug 1988 A
4793362 Tedner Dec 1988 A
4832608 Kroll May 1989 A
4836214 Sramek Jun 1989 A
4890630 Kroll et al. Jan 1990 A
4895163 Libke et al. Jan 1990 A
4899758 Finkelstein et al. Feb 1990 A
4905705 Kizakevich et al. Mar 1990 A
4911175 Shizgal Mar 1990 A
4922911 Wada et al. May 1990 A
4924875 Chamoun May 1990 A
4942880 Sloväk Jul 1990 A
4951682 Petre Aug 1990 A
4981141 Segalowitz Jan 1991 A
5020541 Marriott Jun 1991 A
5025784 Shao et al. Jun 1991 A
5063937 Ezenwa et al. Nov 1991 A
5078134 Heilman et al. Jan 1992 A
5086781 Bookspan Feb 1992 A
5101828 Welkowitz et al. Apr 1992 A
5143079 Frei et al. Sep 1992 A
5184624 Brown et al. Feb 1993 A
5197479 Hubelbank et al. Mar 1993 A
5199432 Quedens et al. Apr 1993 A
5233982 Kohl Aug 1993 A
5246008 Mueller Sep 1993 A
5272624 Gisser et al. Dec 1993 A
5280429 Withers Jan 1994 A
5282840 Hudrlik Feb 1994 A
5284142 Goble et al. Feb 1994 A
5305192 Bonte et al. Apr 1994 A
5309917 Wang et al. May 1994 A
5311878 Brown et al. May 1994 A
5335667 Cha et al. Aug 1994 A
5351697 Cheney et al. Oct 1994 A
5353802 Ollmar Oct 1994 A
5372141 Gallup et al. Dec 1994 A
5381333 Isaacson et al. Jan 1995 A
5390110 Cheney et al. Feb 1995 A
5415164 Faupel e May 1995 A
5421345 Lekholm et al. Jun 1995 A
5423326 Wang et al. Jun 1995 A
5427113 Hiroshi et al. Jun 1995 A
5449000 Libke et al. Sep 1995 A
5454377 Dzwonczyk et al. Oct 1995 A
5465730 Zadehkoochak et al. Nov 1995 A
5469859 Tsoglin et al. Nov 1995 A
5503157 Sramek Apr 1996 A
5505209 Reining Apr 1996 A
5511553 Segalowitz Apr 1996 A
5526808 Kaminsky Jun 1996 A
5529072 Sramek Jun 1996 A
5544662 Saulnier et al. Aug 1996 A
5557242 Wetherell Sep 1996 A
5562607 Gyory Oct 1996 A
5575929 Yu et al. Nov 1996 A
5588429 Isaacson et al. Dec 1996 A
5611351 Sato et al. Mar 1997 A
5615689 Kotler Apr 1997 A
5626146 Barber et al. May 1997 A
5704355 Bridges Jan 1998 A
5730136 Laufer et al. Mar 1998 A
5732710 Rabinovich et al. Mar 1998 A
5735284 Tsoglin et al. Apr 1998 A
5746214 Brown et al. May 1998 A
5759159 Masreliez Jun 1998 A
5788643 Feldman Aug 1998 A
5800350 Coppleson et al. Sep 1998 A
5807251 Wang et al. Sep 1998 A
5807270 Williams Sep 1998 A
5807272 Kun et al. Sep 1998 A
5810742 Pearlman Sep 1998 A
5876353 Riff Mar 1999 A
5919142 Boone et al. Jul 1999 A
5947910 Zimmet Sep 1999 A
5957861 Combs et al. Sep 1999 A
5964703 Goodman et al. Oct 1999 A
5994956 Concorso Nov 1999 A
6006125 Kelly et al. Dec 1999 A
6011992 Hubbard et al. Jan 2000 A
6015389 Brown Jan 2000 A
6018677 Vidrine et al. Jan 2000 A
6101413 Olson et al. Aug 2000 A
6115626 Whayne et al. Sep 2000 A
6122544 Organ Sep 2000 A
6125297 Siconolfi Sep 2000 A
6129666 DeLuca et al. Oct 2000 A
6142949 Ubby Nov 2000 A
6151523 Ferrer et al. Nov 2000 A
6167300 Cherepenin et al. Dec 2000 A
6173003 Whikehart et al. Jan 2001 B1
6228022 Friesem et al. May 2001 B1
6228033 Koobi May 2001 B1
6233473 Shepherd et al. May 2001 B1
6236886 Cherepenin et al. May 2001 B1
6248083 Smith et al. Jun 2001 B1
6253100 Zhdanov Jun 2001 B1
6256532 Cha Jul 2001 B1
6280396 Clark Aug 2001 B1
6292690 Petrucelli et al. Sep 2001 B1
6308097 Pearlman Oct 2001 B1
6339722 Heethaar et al. Jan 2002 B1
6354996 Drinan et al. Mar 2002 B1
6376023 Mori Apr 2002 B1
6432045 Lemperle et al. Aug 2002 B2
6459930 Takehara et al. Oct 2002 B1
6469732 Chang et al. Oct 2002 B1
6472888 Oguma et al. Oct 2002 B2
6496725 Kamada et al. Dec 2002 B2
6497659 Rafert Dec 2002 B1
6501984 Church et al. Dec 2002 B1
6511438 Bernstein et al. Jan 2003 B2
6512949 Combs et al. Jan 2003 B1
6516218 Cheng et al. Feb 2003 B1
6522910 Gregory Feb 2003 B1
6532384 Fukuda Mar 2003 B1
6551252 Sackner et al. Apr 2003 B2
6556001 Wiegand et al. Apr 2003 B1
6560480 Nachaliel et al. May 2003 B1
6561986 Baura et al. May 2003 B2
6564079 Cory et al. May 2003 B1
6569160 Goldin et al. May 2003 B1
6584348 Glukhovsky Jun 2003 B2
6602201 Hepp et al. Aug 2003 B1
6615077 Zhu et al. Sep 2003 B1
6618616 Iijima et al. Sep 2003 B2
6623312 Merry et al. Sep 2003 B2
6625487 Herleikson Sep 2003 B2
6631292 Liedtk Oct 2003 B1
6633777 Szopinski Oct 2003 B2
6636754 Baura et al. Oct 2003 B1
6643543 Takehara et al. Nov 2003 B2
6658296 Wong et al. Dec 2003 B1
6714813 Ishigooka et al. Mar 2004 B2
6714814 Yamada et al. Mar 2004 B2
6723049 Skladnev et al. Apr 2004 B2
6724200 Fukuda Apr 2004 B2
6725089 Komatsu et al. Apr 2004 B2
6760617 Ward et al. Jul 2004 B2
6763263 Gregory et al. Jul 2004 B2
6768921 Organ et al. Jul 2004 B2
6788966 Kenan et al. Sep 2004 B2
6790178 Mault et al. Sep 2004 B1
6807443 Keren Oct 2004 B2
6829501 Nielsen et al. Dec 2004 B2
6829503 Alt Dec 2004 B2
6840907 Brydon Jan 2005 B1
6845264 Skladnev et al. Jan 2005 B1
6870109 Villarreal Mar 2005 B1
6875176 Mourad et al. Apr 2005 B2
6906533 Yoshida Jun 2005 B1
6922586 Davies Jul 2005 B2
6936012 Wells Aug 2005 B2
6940286 Wang et al. Sep 2005 B2
RE38879 Goodman et al. Nov 2005 E
6980852 Jersey-Willuhn et al. Dec 2005 B2
6980853 Miyoshi et al. Dec 2005 B2
7065399 Nakada Jun 2006 B2
7079889 Nakada Jul 2006 B2
7096061 Arad Aug 2006 B2
7122012 Bouton et al. Oct 2006 B2
7130680 Kodama et al. Oct 2006 B2
7132611 Gregaard et al. Nov 2006 B2
7148701 Park et al. Dec 2006 B2
7149573 Wang Dec 2006 B2
7169107 Jersey-Willuhn et al. Jan 2007 B2
7184820 Jersey-Willuhn et al. Feb 2007 B2
7184821 Belalcazar et al. Feb 2007 B2
7186220 Stahmann et al. Mar 2007 B2
7206630 Tarler Apr 2007 B1
7212852 Smith et al. May 2007 B2
7233823 Simond et al. Jun 2007 B2
7251524 Hepp et al. Jul 2007 B1
7288943 Matthiessen et al. Oct 2007 B2
D557809 Neverov et al. Dec 2007 S
7313435 Nakada et al. Dec 2007 B2
7317161 Fukuda Jan 2008 B2
7336992 Shiokawa Feb 2008 B2
7440796 Woo et al. Oct 2008 B2
7457660 Smith et al. Nov 2008 B2
7477937 Iijima et al. Jan 2009 B2
7496450 Ortiz Alemn Feb 2009 B2
7499745 Littrup et al. Mar 2009 B2
D603051 Causevic et al. Oct 2009 S
7603158 Nachman Oct 2009 B2
7603171 Eror et al. Oct 2009 B2
7628761 Gozani et al. Dec 2009 B2
7638341 Rubinsky et al. Dec 2009 B2
7657292 Baker et al. Feb 2010 B2
7660617 Davis Feb 2010 B2
7706872 Min et al. Apr 2010 B2
7711418 Garber et al. May 2010 B2
7729756 Mertelmeier et al. Jun 2010 B2
7733224 Tran Jun 2010 B2
7749013 Sato et al. Jul 2010 B2
7860557 Istvan et al. Dec 2010 B2
7917202 Chamney et al. Mar 2011 B2
D641886 Causevic et al. Jul 2011 S
7983853 Wang et al. Jul 2011 B2
D647208 Rothman et al. Oct 2011 S
8055335 Stylos Nov 2011 B2
8068906 Chetham Nov 2011 B2
8172762 Robertson May 2012 B2
8233617 Johnson et al. Jul 2012 B2
8233974 Ward et al. Jul 2012 B2
D669186 Gozani Oct 2012 S
D669187 Gozani Oct 2012 S
8285356 Bly et al. Oct 2012 B2
D674096 Gaw et al. Jan 2013 S
8467865 Gregory et al. Jun 2013 B2
8744564 Ward et al. Jun 2014 B2
D718458 Vosch et al. Nov 2014 S
D719660 Vosch et al. Dec 2014 S
D728801 Machon et al. May 2015 S
20010007056 Linder et al. Jul 2001 A1
20010007924 Kamada et al. Jul 2001 A1
20010020138 Ishigooka et al. Sep 2001 A1
20010021799 Ohlsson et al. Sep 2001 A1
20010025139 Pearlman Sep 2001 A1
20010051774 Littrup et al. Dec 2001 A1
20020020138 Walker et al. Feb 2002 A1
20020022773 Drinan et al. Feb 2002 A1
20020022787 Takehara et al. Feb 2002 A1
20020035334 Meij et al. Mar 2002 A1
20020072686 Hoey et al. Jun 2002 A1
20020079910 Fukuda Jun 2002 A1
20020093992 Plangger Jul 2002 A1
20020106681 Wexler et al. Aug 2002 A1
20020109621 Khair et al. Aug 2002 A1
20020111559 Kurata et al. Aug 2002 A1
20020123694 Organ et al. Sep 2002 A1
20020138019 Wexler et al. Sep 2002 A1
20020161311 Ward et al. Oct 2002 A1
20020193689 Bernstein et al. Dec 2002 A1
20020194419 Rajput et al. Dec 2002 A1
20030004403 Drinan et al. Jan 2003 A1
20030009111 Cory et al. Jan 2003 A1
20030023184 Pitts-Crick et al. Jan 2003 A1
20030028221 Zhu et al. Feb 2003 A1
20030036713 Bouton et al. Feb 2003 A1
20030050570 Kodama et al. Mar 2003 A1
20030073916 Yonce Apr 2003 A1
20030105410 Pearlman Jun 2003 A1
20030105411 Smallwood et al. Jun 2003 A1
20030120170 Zhu et al. Jun 2003 A1
20030120182 Wilkinson et al. Jun 2003 A1
20030173976 Wiegand et al. Sep 2003 A1
20030176808 Masuo Sep 2003 A1
20030216661 Davies Nov 2003 A1
20030216664 Suarez Nov 2003 A1
20040015095 Li et al. Jan 2004 A1
20040019292 Drinan et al. Jan 2004 A1
20040059220 Mourad et al. Mar 2004 A1
20040059242 Masuo et al. Mar 2004 A1
20040073127 Istvan et al. Apr 2004 A1
20040073130 Bohm et al. Apr 2004 A1
20040077944 Steinberg et al. Apr 2004 A1
20040116819 Alt Jun 2004 A1
20040127793 Mendlein et al. Jul 2004 A1
20040158167 Smith et al. Aug 2004 A1
20040167423 Pillon et al. Aug 2004 A1
20040171961 Smith et al. Sep 2004 A1
20040181163 Wong et al. Sep 2004 A1
20040181164 Smith et al. Sep 2004 A1
20040186392 Ward et al. Sep 2004 A1
20040210150 Virtanen Oct 2004 A1
20040210158 Organ et al. Oct 2004 A1
20040220632 Burnes Nov 2004 A1
20040234113 Miga Nov 2004 A1
20040236202 Burton Nov 2004 A1
20040242987 Liew et al. Dec 2004 A1
20040242989 Zhu et al. Dec 2004 A1
20040243018 Organ et al. Dec 2004 A1
20040252870 Reeves et al. Dec 2004 A1
20040253652 Davies Dec 2004 A1
20040260167 Leonhardt Dec 2004 A1
20040267333 Kronberg Dec 2004 A1
20040267344 Stett et al. Dec 2004 A1
20050033281 Bowman et al. Feb 2005 A1
20050039763 Kraemer et al. Feb 2005 A1
20050049474 Kellogg et al. Mar 2005 A1
20050080460 Wang et al. Apr 2005 A1
20050085743 Hacker et al. Apr 2005 A1
20050098343 Fukuda May 2005 A1
20050101875 Semler et al. May 2005 A1
20050107719 Arad et al. May 2005 A1
20050113704 Lawson et al. May 2005 A1
20050124908 Belalcazar et al. Jun 2005 A1
20050137480 Alt et al. Jun 2005 A1
20050151545 Park et al. Jul 2005 A1
20050177061 Alanen et al. Aug 2005 A1
20050177062 Skrabal et al. Aug 2005 A1
20050192488 Bryenton et al. Sep 2005 A1
20050201598 Harel et al. Sep 2005 A1
20050203435 Nakada Sep 2005 A1
20050203436 Davies Sep 2005 A1
20050215918 Frantz et al. Sep 2005 A1
20050228309 Fisher et al. Oct 2005 A1
20050251062 Choi et al. Nov 2005 A1
20050261743 Kroll Nov 2005 A1
20050283091 Kink et al. Dec 2005 A1
20060004300 Kennedy Jan 2006 A1
20060025701 Kasahara Feb 2006 A1
20060041280 Stahmann et al. Feb 2006 A1
20060047189 Takehara Mar 2006 A1
20060052678 Drinan Mar 2006 A1
20060064029 Arad Mar 2006 A1
20060070623 Wilkinson et al. Apr 2006 A1
20060085048 Cory et al. Apr 2006 A1
20060085049 Cory et al. Apr 2006 A1
20060100532 Bae et al. May 2006 A1
20060111652 McLeod May 2006 A1
20060116599 Davis Jun 2006 A1
20060122523 Bonmassar et al. Jun 2006 A1
20060122540 Zhu et al. Jun 2006 A1
20060135886 Lippert Jun 2006 A1
20060184060 Belalcazar Aug 2006 A1
20060197509 Kanamori et al. Sep 2006 A1
20060200033 Keren et al. Sep 2006 A1
20060224079 Washchuk Oct 2006 A1
20060224080 Oku et al. Oct 2006 A1
20060241513 Hatlestad et al. Oct 2006 A1
20060241719 Foster et al. Oct 2006 A1
20060247543 Cornish et al. Nov 2006 A1
20060252670 Fiorucci et al. Nov 2006 A1
20060253016 Baker et al. Nov 2006 A1
20060258952 Stahmann et al. Nov 2006 A1
20060264775 Mills et al. Nov 2006 A1
20060264776 Stahmann et al. Nov 2006 A1
20060270942 Mcadams Nov 2006 A1
20070007975 Hawkins et al. Jan 2007 A1
20070010758 Matthiessen et al. Jan 2007 A1
20070024310 Tokuno et al. Feb 2007 A1
20070027402 Levin et al. Feb 2007 A1
20070043303 Osypka et al. Feb 2007 A1
20070049993 Hofmann et al. Mar 2007 A1
20070087703 Li et al. Apr 2007 A1
20070088227 Nishimura Apr 2007 A1
20070106342 Schumann May 2007 A1
20070118027 Baker et al. May 2007 A1
20070156061 Hess Jul 2007 A1
20070188219 Segarra Aug 2007 A1
20070246046 Teschner et al. Oct 2007 A1
20070270707 Belalcazar Nov 2007 A1
20080001608 Saulnier Jan 2008 A1
20080002873 Reeves et al. Jan 2008 A1
20080004904 Tran Jan 2008 A1
20080009757 Tsoglin et al. Jan 2008 A1
20080009759 Chetham Jan 2008 A1
20080027350 Webler et al. Jan 2008 A1
20080039700 Drinan et al. Feb 2008 A1
20080048786 Feldkamp et al. Feb 2008 A1
20080051643 Park et al. Feb 2008 A1
20080064981 Gregory Mar 2008 A1
20080091114 Min et al. Apr 2008 A1
20080139957 Hubbard et al. Jun 2008 A1
20080183098 Denison et al. Jul 2008 A1
20080188757 Rovira et al. Aug 2008 A1
20080200802 Bhavaraju et al. Aug 2008 A1
20080205717 Reeves et al. Aug 2008 A1
20080221411 Hausmann et al. Sep 2008 A1
20080247502 Liao Oct 2008 A1
20080252304 Woo et al. Oct 2008 A1
20080262375 Brown et al. Oct 2008 A1
20080270051 Essex et al. Oct 2008 A1
20080287823 Chetham Nov 2008 A1
20080306400 Takehara Dec 2008 A1
20080306402 Singer Dec 2008 A1
20080319336 Ward et al. Dec 2008 A1
20090018432 He Jan 2009 A1
20090043222 Chetham Feb 2009 A1
20090054952 Glukhovsky et al. Feb 2009 A1
20090069708 Hatlestad et al. Mar 2009 A1
20090076343 James et al. Mar 2009 A1
20090076345 Manicka et al. Mar 2009 A1
20090076350 Bly et al. Mar 2009 A1
20090076410 Libbus et al. Mar 2009 A1
20090082679 Chetham Mar 2009 A1
20090084674 Holzhacker et al. Apr 2009 A1
20090093730 Grassl Apr 2009 A1
20090105555 Dacso et al. Apr 2009 A1
20090143663 Chetham Jun 2009 A1
20090177099 Smith et al. Jul 2009 A1
20090209828 Musin Aug 2009 A1
20090209872 Pop Aug 2009 A1
20090216140 Skrabal Aug 2009 A1
20090216148 Freed et al. Aug 2009 A1
20090234244 Tanaka Sep 2009 A1
20090240163 Webler Sep 2009 A1
20090264727 Markowitz Oct 2009 A1
20090264745 Markowitz et al. Oct 2009 A1
20090264776 Vardy Oct 2009 A1
20090264791 Gregory et al. Oct 2009 A1
20090275854 Zielinski et al. Nov 2009 A1
20090275855 Zielinski et al. Nov 2009 A1
20090287102 Ward Nov 2009 A1
20090306535 Davies et al. Dec 2009 A1
20090318778 Dacso et al. Dec 2009 A1
20090326408 Moon Dec 2009 A1
20100007357 Spielberger et al. Jan 2010 A1
20100049077 Sadleir et al. Feb 2010 A1
20100056881 Libbus et al. Mar 2010 A1
20100094160 Eror et al. Apr 2010 A1
20100100003 Chetham et al. Apr 2010 A1
20100100146 Blomqvist Apr 2010 A1
20100106046 Shochat et al. Apr 2010 A1
20100152605 Ward Jun 2010 A1
20100168530 Chetham et al. Jul 2010 A1
20100191141 Aberg Jul 2010 A1
20100228143 Teschner et al. Sep 2010 A1
20110025348 Chetham et al. Feb 2011 A1
20110034806 Hartov et al. Feb 2011 A1
20110046505 Cornish et al. Feb 2011 A1
20110054343 Chetham et al. Mar 2011 A1
20110054344 Slizynski Mar 2011 A1
20110060239 Gaw Mar 2011 A1
20110060241 Martinsen et al. Mar 2011 A1
20110082383 Cory et al. Apr 2011 A1
20110087129 Chetham et al. Apr 2011 A1
20110118619 Burton et al. May 2011 A1
20110190655 Moissl et al. Aug 2011 A1
20110208084 Martinez et al. Aug 2011 A1
20110230784 Slizynski et al. Sep 2011 A2
20110245712 Patterson et al. Oct 2011 A1
20110251513 Chetham et al. Oct 2011 A1
20110274327 Wehnes et al. Nov 2011 A1
20110282180 Goldkuhl et al. Nov 2011 A1
20120071772 Chetham Mar 2012 A1
20120165884 Xi Jun 2012 A1
20120238896 Garber et al. Sep 2012 A1
20130102873 Hamaguchi Apr 2013 A1
20130165760 Erlinger et al. Jun 2013 A1
20130165761 De Limon et al. Jun 2013 A1
20140148721 Erlinger et al. May 2014 A1
20140371566 Raymond et al. Dec 2014 A1
Foreign Referenced Citations (151)
Number Date Country
2231038 Nov 1999 CA
2638958 Jun 2000 CA
2613524 Jan 2007 CA
2615845 Jan 2007 CA
1236597 Dec 1999 CN
1329875 Jan 2002 CN
0357309 Mar 1990 EP
377887 Jul 1990 EP
581073 Feb 1994 EP
339471 Mar 1997 EP
865763 Sep 1998 EP
0869360 Oct 1998 EP
1078597 Feb 2001 EP
1080686 Mar 2001 EP
1112715 Apr 2001 EP
1112715 Jul 2001 EP
1146344 Oct 2001 EP
1114610 Nov 2001 EP
1177760 Feb 2002 EP
1219937 Jul 2002 EP
1238630 Sep 2002 EP
1247487 Oct 2002 EP
1329190 Jul 2003 EP
1338246 Aug 2003 EP
1080686 Mar 2004 EP
1452131 Sep 2004 EP
1553871 Jul 2005 EP
1118308 Nov 2005 EP
1629772 Mar 2006 EP
1247487 Jan 2008 EP
1903938 Apr 2008 EP
1909642 Apr 2008 EP
1948017 Jul 2008 EP
1353595 Aug 2008 EP
2748928 Nov 1997 FR
1441622 Jul 1976 GB
2131558 Jun 1984 GB
2260416 Apr 1993 GB
2426824 Dec 2006 GB
6-74103 Oct 1994 JP
8191808 Jul 1996 JP
10225521 Aug 1998 JP
2000107138 Apr 2000 JP
2001037735 Feb 2001 JP
2001061804 Mar 2001 JP
2001-204707 Jul 2001 JP
2001224568 Aug 2001 JP
2001-245866 Sep 2001 JP
2002502274 Jan 2002 JP
2002238870 Aug 2002 JP
2002350477 Dec 2002 JP
2003-502092 Jan 2003 JP
2003075487 Mar 2003 JP
2003-116803 Apr 2003 JP
2003116805 Apr 2003 JP
2003230547 Aug 2003 JP
200461251 Feb 2004 JP
2006-501892 Jan 2006 JP
2008-502382 Jan 2008 JP
2010-526604 Aug 2010 JP
2112416 Jun 1998 RU
WO 88-07392 Oct 1988 WO
WO 91-19454 Dec 1991 WO
WO 93-18821 Sep 1993 WO
WO 9401040 Jan 1994 WO
WO 94-10922 May 1994 WO
WO 96-01586 Jan 1996 WO
WO 96-12439 May 1996 WO
WO 96-32652 Oct 1996 WO
WO 97-11638 Apr 1997 WO
WO 97-14358 Apr 1997 WO
WO 97-24156 Jul 1997 WO
WO 98-06328 Feb 1998 WO
WO 9812983 Apr 1998 WO
WO 98-23204 Jun 1998 WO
WO 98-33553 Aug 1998 WO
WO 98-51211 Nov 1998 WO
WO 99-42034 Aug 1999 WO
WO 99-48422 Sep 1999 WO
WO 00-19886 Apr 2000 WO
WO 00-40955 Jul 2000 WO
WO 00-78213 Dec 2000 WO
WO 00-79255 Dec 2000 WO
WO 01-27605 Apr 2001 WO
WO 01-50954 Jul 2001 WO
WO 01-52733 Jul 2001 WO
WO 0167098 Sep 2001 WO
WO 02-053028 Jul 2002 WO
WO 02-062214 Aug 2002 WO
WO 02-094096 Nov 2002 WO
WO 2004-000115 Dec 2003 WO
WO 2004002301 Jan 2004 WO
WO 2004006660 Jan 2004 WO
WO 2004-021880 Mar 2004 WO
WO 2004-026136 Apr 2004 WO
WO 2004-030535 Apr 2004 WO
WO 2004-032738 Apr 2004 WO
WO 2004-043252 May 2004 WO
WO 2004-047635 Jun 2004 WO
WO 2004-047636 Jun 2004 WO
WO 2004-047638 Jun 2004 WO
WO 2004-049936 Jun 2004 WO
WO 2004-083804 Sep 2004 WO
WO 2004-084087 Sep 2004 WO
WO 2004-084723 Oct 2004 WO
WO 2004-098389 Nov 2004 WO
WO 2004112563 Dec 2004 WO
WO 2005-010640 Feb 2005 WO
WO 2005-018432 Mar 2005 WO
WO 2005-027717 Mar 2005 WO
WO 2005-051163 Jun 2005 WO
WO 2005-051194 Jun 2005 WO
WO 2005-122881 Dec 2005 WO
WO 2005-122888 Dec 2005 WO
WO 2006-045051 Apr 2006 WO
WO 2006-056074 Jun 2006 WO
WO 2006-129108 Dec 2006 WO
WO 2006-129116 Dec 2006 WO
WO 2007-002991 Jan 2007 WO
WO 2007-002992 Jan 2007 WO
WO 2007-002993 Jan 2007 WO
WO 2007-009183 Jan 2007 WO
WO 2007045006 Apr 2007 WO
WO 2007041783 Apr 2007 WO
WO 2007-056493 May 2007 WO
WO 2007-070997 Jun 2007 WO
WO 2007105996 Sep 2007 WO
WO 2007-128952 Nov 2007 WO
WO 2008-011716 Jan 2008 WO
WO 2008-054426 Aug 2008 WO
WO 2008119166 Oct 2008 WO
WO 2008-119166 Oct 2008 WO
WO 2008-138062 Nov 2008 WO
WO 2008149125 Dec 2008 WO
WO 2009-018620 Feb 2009 WO
WO 2009-027812 Mar 2009 WO
WO 2009-036369 Mar 2009 WO
WO 2009-068961 Jun 2009 WO
WO 2009100491 Aug 2009 WO
WO 2009-112965 Sep 2009 WO
WO 2010-003162 Jan 2010 WO
WO 2010-029465 Mar 2010 WO
WO 2010-069023 Jun 2010 WO
WO 2010-076719 Jul 2010 WO
WO 2011-018744 Feb 2011 WO
WO 2011-022068 Feb 2011 WO
WO 2011-050393 May 2011 WO
WO 2011-075769 Jun 2011 WO
WO 2011-113169 Sep 2011 WO
WO 2011-136867 Nov 2011 WO
WO 2014-176420 Oct 2014 WO
Non-Patent Literature Citations (87)
Entry
Ivorra, Antoni, et al., “Bioimpedance dispersion width as a parameter to monitor living tissues,” Physiol. Meas. 26 (2005) S165-S173.
Locus, www.dictionary.com, printed Nov. 21, 2016 (6 pages).
Cornish, et al., “Optimizing Electrode Sites for Segmental Bioimpedance Measurements” Physiological Measurement, Institute of Physics, 1999, pp. 241-250, vol. 20, No. 3.
Cornish, et al., “A New Technique for the Quantification of Peripheral Edema with Application in Both Unilateral and Bilateral Cases” Angiology, 2002, pp. 41-47, vol. 53, No. 1.
Fenech, et al., “Extracellular and Intracellular Volume Variations During Postural Change Measured by Segmental and Wrist-Ankle Bioimpedance Spectroscopy” IEEE Transactions on Biomedical Engineering, IEEE Service Center, 2004, pp. 166-175, vol. 51, No. 1.
Golden, et al., “Assessment of Peripheral Hemodynmics using Impedance Plethysmogrphy” Physical Therapy, 1986, pp. 1544-1547, vol. 66, No. 10.
Kim, et al., “Impedance Tomography and its Application in Deep Venous Thrombosis Detection” IEEE Engineering in Medicine and Biology Magazine, IEEE Service Center, 1989, pp. 46-49, vol. 8, No. 1.
Nawarycz, et al., “triple-frequency Electroimpedance Method for Evaluation of Body Water Compartments” Medical & Biological Engineering & Computing, 1996, pp. 181-182, vol. 34, No. Supp. 01, Pt. 02.
Noshiro, et al., “Electrical Impedance in the Lower Limbs of Patients with Duchenne Muscular Dystrophy: A Preliminary Study” Medical & Biological Engineering & Computing, 1993, pp. 97-102, vol. 31, No. 2.
Seo, et al., “Measuring Lower Leg Swelling: Optimum Frequency for Impedance Method” Medical &, Biological Engineering & Computing, 2001, pp. 185-189, vol. 39.
Seoane, et al., “Current Source for Wideband Electrical Bioimpedance Spectroscopy Based on a Single Operational Amplifier” World Congress on Medical Physics and Biomedical Engineering 2006, pp. 707-710, vol. 14.
Smith, et al., “A Pilot Study for Tissue Characterization Using Bio-impedance Mapping” 13th International Conference on Electrical Bio-impedance and the 8th Conference on Electrical Impedance Tomography 2007, pp. 146-149.
Stanton, et al., “Non-invasive Assessment of the Lymphedematous Limb” The International Society of Lymphology, 2000, pp. 122-135, vol. 33, No. 3.
Abdullah M. Z.; Simulation of an inverse problem in electrical impedance tomography using resistance electrical network analogues; International Journal of Electrical Engineering Education; vol. 36, No. 4, pp. 311-324; Oct. 1999.
Al-Hatib, F.; Patient Instrument connection errors in bioelectrical impedance measurement; Physiological Measurement; vol. 19, No. 2, pp. 285-296; May 2, 1998.
Bella, et al., Relations of Left Ventricular Mass to Fat-Free and Adipose Body Mass: The Strong Heart Study, (1998) Circulation, vol. 98, pp. 2538-2544.
Boulier, A. et al.; Fat-Free Mass Estimation by Two Electrode Impedance Method; American Journal of Clinical Nutrition; vol. 52, pp. 581-585; 1990.
Bracco, D. et al., Bedside determination of fluid accumulation after cardiac surgery using segmental bioelectrical impedance, Critical Care Medicine, vol. 26, No. 6, pp. 1065-1070, 1998.
Chaudary, S.S. et al.; Dielectric Properties of Normal & Malignant Human Breast Tissues at Radiowave and Microwave Frequencies; Indian Journal of Biochemistry & Biophysics; vol. 21, No. 1, pp. 76-79; 1984.
Cornish, B.H. et al.; Alteration of the extracellular and total body water volumes measured by multiple frequency bioelectrical impedance analysis; Nutrition Research; vol. 14, No. 5, pp. 717-727; 1994.
Cornish, B.H. et al.; Bioelectrical impedance for monitoring the efficacy of lymphoedema treatment programmes; Breast Cancer Research and Treatment; vol. 38, pp. 169-176; 1996.
Cornish, B.H. et al.; Data analysis in multiple-frequency bioelectrical impedance analysis; Physiological Measurement; vol. 19, No. 2, pp. 275-283; May 1, 1998.
Cornish, B.H. et al.; Early diagnosis of lymphedema using multiple frequency bioimpedance; Lymphology; vol. 34, pp. 2-11; Mar. 2001.
Cornish, B.H. et al.; Early diagnosis of lymphoedema in postsurgery breast cancer patients; Annals New York Academy of Sciences; pp. 571-575; May 2000.
Cornish, B.H. et al.; Quantification of Lymphoedema using Multi-frequency Bioimpedance; Applied Radiation and Isotopes; vol. 49, No. 5/6, pp. 651-652; 1998.
De Luca, F. et al., Use of low-frequency electrical impedance measurements to determine phospoholipid content in amniotic fluid; Physics in Medicine and Biology, vol. 41, pp. 1863-1869, 1996.
Deurenberg, P. et al., Multi-frequency bioelectrical impedance: a comparison between the Cole-Cole modelling and Hanai equations with the classically impedance index approach, Annals of Human Biology, vol. 23, No. 1, pp. 31-40, 1996.
Dines K.A. et al.; Analysis of electrical conductivity imaging; Geophysics; vol. 46, No. 7, pp. 1025-1036; Jul. 1981.
Ellis, K.J. et al; Human hydrometry: comparison of multifrequency bioelectrical impedance with 2H2O and bromine dilution; Journal of Applied Physiology; vol. 85, No. 3, pp. 1056-1062; 1998.
Ezenwa, B.N. et al.; Multiple Frequency System for Body Composition Measurement; Proceedings of the Annual International Conference of the Engineering in Medicine and Biology Society; vol. 15; pp. 1020-1021; 1993.
Forslund, A.H. et al.; Evaluation of modified multicompartment models to calculate body composition in healthy males; American Journal of Clinical Nutrition; vol. 63, pp. 856-862; 1996.
Gersing, E.; Impedance spectroscopy on living tissue for determination of the state of Organs; Bioelectrochemistry and Bioenergetics; vol. 45, pp. 145-149; 1998.
Gerth, W.A. et al.; A computer-based bioelectrical impedance spectroscopic system for noninvasive assessment of compartmental fluid redistribution; Third Annual IEEE Symposium on Computer Based Medical Systems, Jun. 3-6, 1990, University of NC. At Chapel Hill; pp. 446-453; Jun. 1990.
Gudivaka R. et al; Single- and multifrequency models for bioelectrical impedance analysis of body water compartments; Applied Physiology; vol. 87, Issue 3, pp. 1087-1096; 1999.
Iacobellis, G., et al. Influence of Excess Fat on Cardiac Morphology and Function: Study in Uncomplicated Obesity, (2002) Obesity Research, vol. 10, pp. 767-773.
Jones, C.H. et al; Extracellular fluid volume determined by bioelectric impedance and serum albumin in CAPD patients; Nephrology Dialysis Transplantation; vol. 13, pp. 393-397; 1998.
Jossinet, J. et al.; A Study for Breast Imaging with a Circular Array of Impedance Electrodes; Proc. Vth Int. Conf. Bioelectrical Impedance, 1981, Tokyo, Japan; pp. 83-86; 1981.
Jossinet, J. et al.; Technical Implementation and Evaluation of a Bioelectrical Breast Scanner; Proc. 10.sup.th Int. Conf. IEEE Engng. Med. Biol., 1988, New Orleans, USA (Imped. Imaging II); vol. 1.p. 289; 1988.
Kanai, H. et al.; Electrical Measurement of Fluid Distribution in Legs and Arms; Medical Progress through technology; pp. 159-170; 1987.
Karason, K., et al., Impact of Blood Pressure and Insulin on the Relationship Between Body Fat and Left Ventricular Structure, (2003) European Heart Journal, vol. 24, pp. 1500-1505.
Liu R. et al; Primary Multi-frequency Data Analyze in Electrical Impedance Scanning; Proceedings of the IEEE-EMBS 2005, 27th Annual International Conference of the Engineering in Medicine and Biology Society, Shanghai, China; pp. 1504-1507; , Sep. 1-4, 2005.
Lozano, A. et al.; Two-frequency impedance plethysmograph: real and imaginary parts; Medical & Biological Engineering & Computing; vol. 28, No. 1, pp. 38-42; Jan. 1990.
Lukaski, H.C. et al.; Estimation of Body Fluid Volumes Using Tetrapolar Bioelectrical Impedance Measurements; Aviation, Space, and Environmental Medicine; pp. 1163-1169; Dec. 1988.
Man, B. et al. Results of Preclinical Tests for Breast Cancer Detection by Dielectric Measurements; XII Int. Conf. Med. Biol. Engng. 1979, Jerusalem, Israel. Springer Int., Berlin; Section 30.4; 1980.
Mattar, J.A., Application of Total Body Impedance to the Critically Ill Patient, New Horizons, vol. 4, No. 4, pp. 493-503, Nov. 1996.
McCullah, et al.; Bioelectrical Impedance Analysis Measures the Ejection Fraction of the Calf Muscle Pump; IFMBE Proceedings; vol. 17, pp. 616-619; 2007.
McDougal D., et al.; Body Composition Measurements From Whole Body Resistance and Reactance; Surgical Forum; vol. 36, pp. 43-44; 1986.
Osterman K.S. et al.; Multifrequency electrical impedance imaging: preliminary in vivo experience in breast; Physiological Measurement; vol. 21, No. 1, pp. 99-109; Feb. 2000.
Ott, M. et al.; Bioelectrical Impedance Analysis as a Predictor of Survival in Patients with Human Immunodeficiency Virus Infection; Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology; vol. 9, pp. 20-25; 1995.
Pethig, R. et al.; The Passive Electrical Properties of Biological Systems: Their Significance in Physiology, Biophysics and Biotechnology; Physics in Medicine and Biology; vol. 32, pp. 933-970; 1987.
Piperno, G. et al.; Breast Cancer Screening by Impedance Measurements; Frontiers of Medical & Biological Engineering; vol. 2, pp. 111-117; 1990.
Rigaud, B. et al.; Bioelectrical Impedance Techniques in Medicine; Critical Reviews in Biomedical Engineering; vol. 24 (4-6), pp. 257-351; 1996.
Scharfetter, H. et al.; Effect of Postural Changes on the Reliability of Volume Estimations from Bioimpedance Spectroscopy Data; Kidney International; vol. 51, No. 4, pp. 1078-2087; 1997.
Schneider, I.; Broadband signals for electrical impedance measurements for long bone fractures; Engineering in Medicine and Biology Society, 1996. Bridging Disciplines for Biomedicine. Proceedings of the 18th Annual International Conference of the IEEE; vol. 5, pp. 1934-1935; Oct. 31, 1996.
Skidmore, R. et al.; A Data Collection System for Gathering Electrical Impedance Measurements from the Human Breast; Clinical Physics Physiological Measurement; vol. 8, pp. 99-102; 1987.
Sollish, B.D. et al.; Microprocessor-assisted Screening Techniques; Israel Journal of Medical Sciences; vol. 17, pp. 859-864; 1981.
Steijaert, M. et al.; The use of multi-frequency impedance to determine total body water and extracellular water in obese and lean female individuals; International Journal of Obesity; vol. 21, pp. 930-934; 1997.
Surowiec, A.J. et al.; Dielectric Properties of Brest Carcinoma and the Surrounding Tissues; IEEE Transactions on Biomedical Engineering; vol. 35, pp. 257-263; 1988.
Tedner, B.; Equipment Using Impedance Technique for Automatic Recording of Fluid-Volume Changes During Haemodialysis; Medical & Biological Engineering & Computing; pp. 285-290; 1983.
Thomas. B.J. et al.; Bioelectrical impedance analysis for measurement of body fluid volumes—A review; Journal of Clinical Engineering; vol. 17, No. 16, pp. 505-510; 1992.
Thomas. B.J. et al.; Bioimpedance Spectrometry in Determination of Body Water Compartments: Accuracy and Clinical Significance; Applied Radiation and Isotopes; vol. 49, No. 5/6, pp. 447-455; 1998.
Thomas. B.J.; Future Technologies; Asia Pacific Journal Clinical Nutrition; vol. 4, pp. 157-159; 1995.
Ulgen, Y. et al.; Electrical parameters of human blood; Engineering in Medicine and Biology Society, 1998. Proceedings of the 20th Annual International Conference of the IEEE; vol. 6, pp. 2983-2986; Nov. 1, 1998.
Ward, L.C. et al., Multi-frequency bioelectrical impedance augments the diagnosis and management of lymphoedema in post-mastectomy patients, European Journal of Clinical Investigation, vol. 22, pp. 751-754, 1992.
Ward, L.C. et al.; Determination of Cole parameters in multiple frequency bioelectrical impedance analysis using only the measurement of impedances; Four-frequency fitting; Physiological Measurement; vol. 27, No. 9, pp. 839-850; Sep. 2006.
Ward, L.C. et al.; There is a better way to measure Lymphoedema; National Lymphedema Network Newsletter; vol. 7, No. 4, pp. 89-92; Oct. 1995.
Woodrow, G. et al; Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis; Nephrology Dialysis Transplantation; vol. 15, pp. 862-866; 2000.
Yamakoshi, K.; Non-Invasive Cardiovascular Hemodynamic Measurements; Sensors in Medicine and Health Care; pp. 107-160; 2004.
Yoshinaga, M., Effect of Total Adipose Weight and Systemic Hypertension on Left Ventricular Mass in Children, American Journal of Cardiology, (1995) vol. 76, pp. 785-787.
Blad et al.; Impedance Spectra of Tumour Tissue in Tomparison with Normal Tissue; A Possible Clinical Application for Electrical Impedance Tomography; Physiological Measurement; vol. 17, pp. A105-A115; 1996.
De Lorenzo et al.; Determination of Intracellular Water by Multifrequency Bioelectrical Impedance; Ann. Nutr. Metab.; vol. 39, pp. 177-184; 1995.
Edwards, L.S.; A Modified Pseudosection for Resistivity and IP; Geophysics; vol. 42, No. 5, pp. 1020-1036; 1977.
Hansen, E.; On the Influence of Shape and Variations in Conductivity of the Sample on Four-Point Measurements; Applied Scientific Research; Section B; vol. 8, Issue 1, pp. 93-104 1960.
Igel, J.; On the Small-Scale Variability of Electrical Soil Properties and Its Influence on Geophysical Measurements; Ph.D. Thesis; Frankfurt University; Hanover, Germany; p. 188; 2007.
Kyle et al.; Bioelectrical Impedance Analysis—Part I: Review of Principles and Methods; Clinical Nutrition; vol. 23, pp. 1226-1243; 2004.
Loke et al.; Least Squares Deconvolution of Apparent Resistivity Pseudosections; Geophysics; vol. 60, No. 6, pp. 1682-1690; 1995.
McAdams et al; Tissue Impedance: a Historical Overview Physiological Measurement; Institute of Physics Publishing; vol. 16. (3A), pp. A1-A13; 1995.
McEwan et al.; Battery Powered and Wireless Electrical Impedance Tomography Spectroscopy Imaging Ssing Bluetooth; Medicon IFMBE Proceedings; vol. 16, pp. 798-801; 2007.
Roy, A.; Depth of investigation in Direct Current Methods Geophysics; vol. 36, pp. 943-959; 1971.
Wilson et al.; Feasibility Studies of Electrical Impedance Spectroscopy for Monitoring Tissue Response to Photodynamic Therapy; Optical Methods for Tumor Treatment and Detections: Mechanisms and Techniques in Photodynamic Therapy VII; Proc. SPIE 3247; pp. 69-80; 1998.
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2009/000163 dated Apr. 16, 2009.
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2006/000922 dated Oct. 13, 2006.
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2006/001057 dated Oct. 25, 2006.
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2008/000034 dated Mar. 17, 2008.
International Search Report and Written Opinion of the International Searching Authority issued in PCT/CA2008/000588 dated Aug. 13, 2008.
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2006/000924 dated Oct. 5, 2006.
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2008/001521 dated Jan. 15, 2009.
Related Publications (1)
Number Date Country
20130131538 A1 May 2013 US